



Belgian Cancer Registry

CANCER FACT SHEET 2022

HEAD AND NECK CANCER

ICD-10 C00-C14; C30-C32



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

HPV: Human Papillomavirus is a sexually transmitted infection and a risk factor for the development of some H&N cancers.

H&N cancer is divided in sub-locations according to ICD-10 codes:

- **Lip:** C00
- **Oral cavity:** C02-C05.0; C06
- **Oropharynx:** C01; C05.1-C05.9; C09-C10

- **Nasopharynx:** C11
- **Hypopharynx:** C12-C13
- **Larynx:** C32
- **Nasal cavity and paranasal sinuses:** C30-C31
- **Salivary glands:** C07-C08
- **Other and ill-defined sites:** C14



1. CANCER INCIDENCE	5
1.1. Head & Neck cancer incidence: by region	5
1.1.1. Head & Neck cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Head & Neck cancer incidence: by tumour stage	7
1.2.2. Head & Neck cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	7
1.2.3. Head & Neck cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.2.4. Head & Neck cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.2.5. Head & Neck cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	9
2. CANCER INCIDENCE TRENDS	12
2.1. Head & Neck cancer incidence trends: by region.....	12
2.1.1. Head & Neck cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	12
2.1.2. Head & Neck cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	13
2.2. Head & Neck cancer incidence trends: by tumour stage	14
2.2.3. Head & Neck cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards...	14
2.3. Head & Neck cancer incidence trends: by age group	16
2.3.4. Head & Neck cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	16
2.3.5. Head & Neck cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	17
3. CANCER PREVALENCE	18
3.1. Head & Neck cancer prevalence: by region.....	18
3.1.1. Head & Neck cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022	18
4. CANCER SURVIVAL.....	19
4.1. Head & Neck cancer survival: by region	19
4.1.1. Head & Neck cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022.....	19
4.2. Head & Neck cancer survival: by sub-location and tumour stage.....	21
4.2.2. Head & Neck cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022.....	21
4.2.3. Head & Neck cancer survival by sub-location, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022.....	28
4.2.4. Head & Neck cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2013-2022.....	35

5. CANCER SURVIVAL TRENDS.....	44
5.1. Head & Neck cancer survival trends: by tumour stage.....	44
5.1.1. Head & Neck cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022	44
6. CANCER MORTALITY	46
6.1. Head & Neck cancer mortality: by region.....	46
6.1.1. Head & Neck cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	46
7. CANCER MORTALITY TRENDS.....	48
7.1. Head & Neck cancer mortality trends: by region	48
7.1.1. Head & Neck cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	48
7.1.2. Head & Neck cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	50

1. CANCER INCIDENCE



1.1. Head & Neck cancer incidence: by region

1.1.1. *Head & Neck cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	0	0	1	3	4	6	9	19	28	47	127	252	384	379	266	193	124	69	27	5	1,943	35.1
	[0.0]	[0.0]	[0.3]	[0.9]	[1.2]	[1.6]	[2.4]	[5.1]	[7.4]	[12.5]	[32.1]	[62.4]	[104.1]	[121.3]	[100.8]	[101.5]	[97.9]	[88.0]	[89.9]	[85.5]	[34.0]	(33.5; 36.7)
Brussels	0	0	0	0	1	1	2	2	4	6	15	23	37	17	14	13	10	5	1	1	152	35.5
	[0.0]	[0.0]	[0.0]	[0.0]	[2.6]	[2.0]	[3.9]	[4.3]	[8.7]	[13.8]	[37.1]	[66.3]	[132.3]	[80.3]	[84.7]	[106.8]	[123.8]	[98.3]	[46.1]	[187.6]	[25.3]	(29.7; 41.3)
Flanders	0	0	1	2	2	5	3	13	15	25	71	128	203	221	155	111	80	50	20	2	1,107	32.6
	[0.0]	[0.0]	[0.5]	[1.1]	[1.1]	[2.5]	[1.4]	[6.2]	[6.9]	[11.8]	[30.7]	[52.4]	[90.3]	[115.1]	[95.9]	[89.9]	[95.7]	[95.3]	[100.4]	[52.9]	[33.4]	(30.6; 34.5)
Wallonia	0	0	0	1	1	0	4	4	9	16	41	101	144	141	97	69	34	14	6	2	684	39.8
	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[0.0]	[3.4]	[3.5]	[7.8]	[13.3]	[32.9]	[80.7]	[124.0]	[142.1]	[113.0]	[126.4]	[97.2]	[67.0]	[75.7]	[130.0]	[38.2]	(36.8; 42.9)
Females																						
Belgium	0	0	1	1	4	3	7	9	22	26	48	93	119	143	104	94	55	27	14	8	778	12.7
	[0.0]	[0.0]	[0.3]	[0.3]	[1.2]	[0.8]	[1.8]	[2.4]	[5.8]	[7.1]	[12.4]	[23.3]	[31.6]	[43.0]	[35.2]	[40.7]	[30.9]	[20.0]	[20.2]	[39.0]	[13.2]	(11.8; 13.6)
Brussels	0	0	0	0	0	0	0	1	3	4	5	6	8	7	6	12	4	1	0	1	58	11.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[6.7]	[9.9]	[13.4]	[17.8]	[26.9]	[28.1]	[28.1]	[69.6]	[30.7]	[9.9]	[0.0]	[48.5]	[9.3]	(8.7; 14.8)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	1	4	1	3	5	11	11	25	43	64	81	65	49	37	20	10	5	435	11.8
	[0.0]	[0.0]	[0.0]	[0.6]	[2.2]	[0.5]	[1.4]	[2.4]	[5.1]	[5.3]	[11.1]	[18.1]	[28.5]	[41.0]	[37.4]	[34.3]	[33.0]	[23.5]	[23.5]	[41.4]	[12.9]	(10.7; 12.9)
Wallonia	0	0	1	0	0	2	4	3	8	11	18	44	47	55	33	33	14	6	4	2	285	14.6
	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[1.9]	[3.4]	[2.6]	[6.9]	[9.2]	[14.5]	[34.7]	[38.4]	[50.0]	[32.9]	[46.6]	[26.3]	[15.2]	[19.0]	[31.4]	[15.2]	(12.9; 16.3)

1.2. Head & Neck cancer incidence: by tumour stage

1.2.2. Head & Neck cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	108 [3.2]	226 [23.9]	90 [20.9]	424 [7.4]	7.7 (6.9; 8.4)	65 [2.0]	81 [8.1]	37 [5.8]	183 [3.1]	3.0 (2.6; 3.5)
II	78 [2.3]	144 [15.2]	77 [17.9]	299 [5.2]	5.5 (4.8; 6.1)	44 [1.3]	63 [6.3]	29 [4.6]	137 [2.3]	2.3 (1.9; 2.7)
III	74 [2.2]	155 [16.4]	77 [17.9]	307 [5.4]	5.6 (4.9; 6.2)	33 [1.0]	58 [5.8]	24 [3.8]	115 [2.0]	1.9 (1.5; 2.2)
IV	185 [5.5]	410 [43.4]	130 [30.2]	725 [12.7]	13.0 (12.0; 13.9)	55 [1.7]	124 [12.3]	78 [12.3]	257 [4.4]	4.1 (3.6; 4.6)
X/NA	50 [1.5]	94 [9.9]	44 [10.2]	188 [3.3]	3.4 (2.9; 3.9)	16 [0.5]	40 [4.0]	30 [4.7]	86 [1.5]	1.4 (1.1; 1.7)

1.2.3. Head & Neck cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	69 [2.1]	149 [15.8]	57 [13.2]	275 [4.8]	5.0 (4.4; 5.6)	56 [1.7]	71 [7.1]	25 [3.9]	152 [2.6]	2.5 (2.1; 2.9)
II	36 [1.1]	75 [7.9]	25 [5.8]	136 [2.4]	2.5 (2.0; 2.9)	19 [0.6]	27 [2.7]	18 [2.8]	65 [1.1]	1.1 (0.8; 1.3)
III	35 [1.0]	63 [6.7]	19 [4.4]	117 [2.0]	2.1 (1.7; 2.4)	15 [0.5]	16 [1.6]	15 [2.4]	46 [0.8]	0.8 (0.5; 1.0)
IV	61 [1.8]	140 [14.8]	41 [9.5]	243 [4.3]	4.4 (3.8; 4.9)	22 [0.7]	59 [5.9]	15 [2.4]	96 [1.6]	1.6 (1.3; 1.9)
X/NA	294 [8.8]	602 [63.7]	276 [64.0]	1,172 [20.5]	21.2 (20.0; 22.5)	101 [3.1]	193 [19.2]	125 [19.7]	419 [7.1]	6.8 (6.1; 7.4)

1.2.4. Head & Neck cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	114 [3.4]	245 [25.9]	91 [21.1]	450 [7.9]	8.1 (7.4; 8.9)	73 [2.2]	94 [9.4]	36 [5.7]	203 [3.5]	3.4 (2.9; 3.8)
II	78 [2.3]	155 [16.4]	78 [18.1]	311 [5.4]	5.7 (5.0; 6.3)	39 [1.2]	62 [6.2]	30 [4.7]	132 [2.2]	2.2 (1.8; 2.6)
III	81 [2.4]	160 [16.9]	79 [18.3]	320 [5.6]	5.8 (5.1; 6.4)	33 [1.0]	53 [5.3]	32 [5.0]	118 [2.0]	1.9 (1.6; 2.3)
IV	184 [5.5]	407 [43.0]	140 [32.5]	732 [12.8]	13.2 (12.2; 14.1)	58 [1.8]	138 [13.7]	79 [12.5]	275 [4.7]	4.4 (3.9; 4.9)
X/NA	38 [1.1]	62 [6.6]	30 [7.0]	130 [2.3]	2.4 (2.0; 2.8)	10 [0.3]	19 [1.9]	21 [3.3]	50 [0.9]	0.8 (0.6; 1.0)

1.2.5. Head & Neck cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

locations	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages	15-59	60-74	75+	All ages		
Lip C00	I	2 [0.1]	4 [0.4]	5 [1.2]	11 [0.2]	0.2 (0.1; 0.4)	4 [0.1]	4 [0.4]	4 [0.6]	12 [0.2]	0.2 (0.1; 0.3)
	II	0 [0.0]	3 [0.3]	2 [0.5]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	2 [0.3]	2 [0.0]	0.0 (0.0; 0.1)
	III	0 [0.0]	1 [0.1]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	IV	1 [0.0]	1 [0.1]	1 [0.2]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
	X/NA	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Oral cavity C02-C05.0;C06	I	28 [0.8]	58 [6.1]	15 [3.5]	101 [1.8]	1.8 (1.4; 2.2)	19 [0.6]	28 [2.8]	11 [1.7]	58 [1.0]	1.0 (0.7; 1.2)
	II	21 [0.6]	42 [4.4]	13 [3.0]	76 [1.3]	1.4 (1.1; 1.7)	13 [0.4]	18 [1.8]	16 [2.5]	47 [0.8]	0.8 (0.5; 1.0)
	III	30 [0.9]	37 [3.9]	16 [3.7]	83 [1.5]	1.5 (1.2; 1.8)	10 [0.3]	14 [1.4]	14 [2.2]	38 [0.6]	0.6 (0.4; 0.8)
	IV	44 [1.3]	109 [11.5]	38 [8.8]	192 [3.4]	3.5 (3.0; 3.9)	14 [0.4]	48 [4.8]	44 [6.9]	106 [1.8]	1.6 (1.3; 2.0)
	X/NA	4 [0.1]	6 [0.6]	4 [0.9]	14 [0.2]	0.3 (0.1; 0.4)	4 [0.1]	2 [0.2]	5 [0.8]	11 [0.2]	0.2 (0.1; 0.3)
Pharynx C01;C05.1-C05.9;C09-C13	I	44 [1.3]	83 [8.8]	17 [3.9]	144 [2.5]	2.5 (2.1; 2.9)	23 [0.7]	29 [2.9]	14 [2.2]	66 [1.1]	1.1 (0.8; 1.4)
	II	36 [1.1]	66 [7.0]	32 [7.4]	134 [2.3]	2.4 (2.0; 2.8)	14 [0.4]	24 [2.4]	9 [1.4]	47 [0.8]	0.8 (0.6; 1.0)
	III	35 [1.0]	63 [6.7]	22 [5.1]	120 [2.1]	2.2 (1.8; 2.5)	14 [0.4]	25 [2.5]	7 [1.1]	46 [0.8]	0.8 (0.5; 1.0)
	IV	96 [2.9]	201 [21.3]	58 [13.5]	355 [6.2]	6.3 (5.7; 7.0)	33 [1.0]	64 [6.4]	22 [3.5]	119 [2.0]	2.0 (1.6; 2.3)
	X/NA	12 [0.4]	29 [3.1]	10 [2.3]	51 [0.9]	0.9 (0.7; 1.2)	3 [0.1]	10 [1.0]	4 [0.6]	17 [0.3]	0.3 (0.1; 0.4)
Oropharynx C01;C05.1-C05.9;C09-C10	I	42 [1.3]	78 [8.2]	16 [3.7]	136 [2.4]	2.4 (2.0; 2.8)	16 [0.5]	27 [2.7]	12 [1.9]	55 [0.9]	0.9 (0.7; 1.2)
	II	24 [0.7]	53 [5.6]	23 [5.3]	100 [1.8]	1.8 (1.5; 2.2)	7 [0.2]	21 [2.1]	6 [0.9]	34 [0.6]	0.6 (0.4; 0.8)
	III	23 [0.7]	40 [4.2]	18 [4.2]	81 [1.4]	1.5 (1.1; 1.8)	6 [0.2]	19 [1.9]	5 [0.8]	30 [0.5]	0.5 (0.3; 0.7)
	IV	50 [1.5]	102 [10.8]	31 [7.2]	183 [3.2]	3.2 (2.8; 3.7)	20 [0.6]	49 [4.9]	13 [2.1]	82 [1.4]	1.4 (1.1; 1.6)
	X/NA	10 [0.3]	21 [2.2]	9 [2.1]	40 [0.7]	0.7 (0.5; 1.0)	3 [0.1]	6 [0.6]	4 [0.6]	13 [0.2]	0.2 (0.1; 0.3)
Nasopharynx C11	I	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	4 [0.1]	1 [0.1]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)

Locations	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages			15-59	60-74	75+	All ages
	II	6 [0.2]	3 [0.3]	2 [0.5]	11 [0.2]	0.2 (0.1; 0.3)	6 [0.2]	1 [0.1]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)
	III	5 [0.1]	6 [0.6]	1 [0.2]	12 [0.2]	0.2 (0.1; 0.3)	5 [0.2]	1 [0.1]	0 [0.0]	6 [0.1]	0.1 (0.0; 0.2)
	IV	10 [0.3]	4 [0.4]	2 [0.5]	16 [0.3]	0.3 (0.1; 0.4)	5 [0.2]	2 [0.2]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)
	X/NA	1 [0.0]	1 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Hypopharynx C12-C13	I	1 [0.0]	5 [0.5]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)	3 [0.1]	1 [0.1]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
	II	6 [0.2]	10 [1.1]	7 [1.6]	23 [0.4]	0.4 (0.2; 0.6)	1 [0.0]	2 [0.2]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.1)
	III	7 [0.2]	17 [1.8]	3 [0.7]	27 [0.5]	0.5 (0.3; 0.7)	3 [0.1]	5 [0.5]	2 [0.3]	10 [0.2]	0.2 (0.1; 0.3)
	IV	36 [1.1]	95 [10.0]	25 [5.8]	156 [2.7]	2.8 (2.3; 3.2)	8 [0.2]	13 [1.3]	8 [1.3]	29 [0.5]	0.5 (0.3; 0.6)
	X/NA	1 [0.0]	7 [0.7]	1 [0.2]	9 [0.2]	0.2 (0.1; 0.3)	0 [0.0]	4 [0.4]	0 [0.0]	4 [0.1]	0.1 (0.0; 0.1)
Larynx C32	I	26 [0.8]	92 [9.7]	50 [11.6]	168 [2.9]	3.1 (2.6; 3.6)	8 [0.2]	18 [1.8]	6 [0.9]	32 [0.5]	0.5 (0.3; 0.7)
	II	13 [0.4]	27 [2.9]	22 [5.1]	62 [1.1]	1.1 (0.9; 1.4)	3 [0.1]	13 [1.3]	1 [0.2]	17 [0.3]	0.3 (0.1; 0.4)
	III	11 [0.3]	44 [4.7]	27 [6.3]	82 [1.4]	1.5 (1.2; 1.8)	3 [0.1]	7 [0.7]	5 [0.8]	15 [0.3]	0.2 (0.1; 0.4)
	IV	25 [0.7]	77 [8.1]	23 [5.3]	125 [2.2]	2.3 (1.9; 2.7)	6 [0.2]	16 [1.6]	4 [0.6]	26 [0.4]	0.4 (0.3; 0.6)
	X/NA	6 [0.2]	7 [0.7]	6 [1.4]	19 [0.3]	0.4 (0.2; 0.5)	1 [0.0]	0 [0.0]	3 [0.5]	4 [0.1]	0.1 (0.0; 0.1)
Nasal cavity and paranasal sinuses C30-C31	I	5 [0.1]	7 [0.7]	2 [0.5]	14 [0.2]	0.3 (0.1; 0.4)	4 [0.1]	4 [0.4]	0 [0.0]	8 [0.1]	0.1 (0.0; 0.2)
	II	2 [0.1]	7 [0.7]	2 [0.5]	11 [0.2]	0.2 (0.1; 0.3)	4 [0.1]	1 [0.1]	1 [0.2]	6 [0.1]	0.1 (0.0; 0.2)
	III	3 [0.1]	10 [1.1]	10 [2.3]	23 [0.4]	0.4 (0.3; 0.6)	2 [0.1]	4 [0.4]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)
	IV	12 [0.4]	6 [0.6]	12 [2.8]	30 [0.5]	0.6 (0.4; 0.8)	4 [0.1]	4 [0.4]	3 [0.5]	11 [0.2]	0.2 (0.1; 0.3)
	X/NA	7 [0.2]	9 [1.0]	2 [0.5]	18 [0.3]	0.3 (0.2; 0.5)	2 [0.1]	3 [0.3]	7 [1.1]	12 [0.2]	0.2 (0.1; 0.3)
Salivary glands C07-C08	I	9 [0.3]	1 [0.1]	2 [0.5]	12 [0.2]	0.2 (0.1; 0.3)	15 [0.5]	11 [1.1]	1 [0.2]	27 [0.5]	0.5 (0.3; 0.6)
	II	6 [0.2]	10 [1.1]	7 [1.6]	23 [0.4]	0.4 (0.3; 0.6)	5 [0.2]	6 [0.6]	1 [0.2]	13 [0.2]	0.2 (0.1; 0.3)
	III	2 [0.1]	5 [0.5]	3 [0.7]	10 [0.2]	0.2 (0.1; 0.3)	4 [0.1]	3 [0.3]	4 [0.6]	11 [0.2]	0.2 (0.1; 0.3)
	IV	6 [0.2]	13 [1.4]	8 [1.9]	27 [0.5]	0.5 (0.3; 0.7)	1 [0.0]	5 [0.5]	6 [0.9]	12 [0.2]	0.2 (0.1; 0.3)

locations	Stage	Males				Females					
		N[CR]				ESR2013 (95%CI)					
		15-59	60-74	75+	All ages	15-59	60-74	75+	All ages		
	X/NA	3 [0.1]	7 [0.7]	5 [1.2]	15 [0.3]	0.3 (0.1; 0.4)	0 [0.0]	4 [0.4]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
Other and ill-defined sites C14	I	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	X/NA	6 [0.2]	4 [0.4]	3 [0.7]	13 [0.2]	0.2 (0.1; 0.4)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)

2. CANCER INCIDENCE TRENDS



2.1. Head & Neck cancer incidence trends: by region

2.1.1. *Head & Neck cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
Belgium	N	1,953	1,856	1,781	1,982	1,955	1,969	1,838	2,027	1,967	1,997	2,019	1,964	2,015	2,008	1,996	2,076	1,836	1,952	1,943		
	CR	38.4	36.3	34.6	38.3	37.4	37.4	34.6	37.7	36.3	36.7	36.9	35.7	36.4	36.1	35.7	36.9	32.4	34.4	34.0		
	ESR2013	44.6	41.9	39.3	43.1	42.0	42.1	38.7	42.0	40.1	40.1	40.2	38.6	38.9	38.3	37.9	38.8	34.0	35.7	35.1	-1.1 (-1.4; -0.7)	2004-2022
Brussels	N	168	161	173	200	163	160	160	176	155	166	168	171	175	152	141	161	132	154	152		
	CR	35.0	33.3	35.3	40.3	32.3	31.0	30.4	32.4	28.0	29.6	29.6	29.9	30.2	26.1	24.0	27.2	22.1	25.7	25.3		
	ESR2013	46.4	45.0	48.6	55.4	45.2	44.2	43.1	47.5	41.2	42.3	44.1	43.9	43.9	39.1	34.2	39.7	32.3	38.3	35.5	-1.8 (-2.5; -1.1)	2004-2022
Flanders	N	1,062	969	974	1,017	1,022	1,055	1,003	1,080	1,058	1,123	1,113	1,073	1,081	1,110	1,127	1,181	1,053	1,090	1,107		
	CR	35.8	32.5	32.5	33.7	33.6	34.4	32.5	34.7	33.7	35.6	35.2	33.7	33.8	34.5	34.8	36.2	32.1	33.1	33.4		
	ESR2013	40.8	36.5	35.7	36.8	36.4	37.6	35.0	37.3	35.7	37.1	36.4	34.5	34.3	34.5	35.1	36.1	32.0	32.6	32.6	-0.8 (-1.1; -0.5)	2004-2022
Wallonia	N	723	726	634	765	770	754	675	771	754	708	738	720	759	746	728	734	651	708	684		
	CR	44.1	44.1	38.3	45.9	45.9	44.7	39.7	45.0	43.7	40.8	42.4	41.1	43.2	42.3	41.1	41.3	36.5	39.7	38.2		
	ESR2013	51.5	51.5	43.2	51.9	52.2	50.2	44.8	49.5	48.1	45.0	46.2	44.9	46.5	45.7	44.0	43.6	38.1	41.3	39.8	-1.3 (-1.8; -0.8)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Head & Neck cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Belgium	N	557	560	532	548	587	637	617	667	694	652	688	739	697	703	760	713	711	838	778		
	CR	10.5	10.5	9.9	10.1	10.8	11.6	11.2	12.0	12.3	11.5	12.1	13.0	12.2	12.2	13.2	12.3	12.2	14.3	13.2		
	ESR2013	10.9	10.9	10.3	10.4	11.0	12.0	11.4	12.1	12.5	11.6	12.2	12.9	12.0	11.9	12.8	11.9	11.8	13.8	12.7	1.0 (0.6; 1.5)	2004-2022
Brussels	N	61	67	71	51	56	66	66	70	72	54	54	71	62	69	79	59	50	66	58		
	CR	11.7	12.8	13.4	9.5	10.3	12.0	11.7	12.1	12.3	9.1	9.0	11.8	10.2	11.3	12.9	9.6	8.1	10.6	9.3		
	ESR2013	13.4	14.8	16.1	11.4	12.4	14.6	14.3	14.5	15.2	10.9	11.3	14.2	12.3	14.1	16.3	11.7	10.2	13.1	11.8	-0.8 (-2.0; 0.3)	2004-2022
Flanders	N	268	286	248	270	289	307	310	335	358	365	347	389	368	353	410	396	403	426	435		
	CR	8.8	9.3	8.0	8.7	9.3	9.8	9.8	10.5	11.1	11.3	10.7	11.9	11.2	10.7	12.4	11.9	12.0	12.7	12.9		
	ESR2013	9.0	9.6	8.2	8.7	9.1	9.8	9.8	10.3	10.8	11.0	10.3	11.4	10.6	9.9	11.5	11.1	11.1	11.7	11.8	1.6 (1.1; 2.1)	2004-2022
Wallonia	N	228	207	213	227	242	264	241	262	264	233	287	279	267	281	271	258	258	346	285		
	CR	13.1	11.8	12.1	12.8	13.6	14.8	13.4	14.5	14.5	12.7	15.6	15.2	14.5	15.2	14.6	13.9	13.8	18.6	15.2		
	ESR2013	13.7	12.5	12.7	13.3	14.2	15.3	13.6	14.8	14.9	13.0	15.7	15.2	14.2	15.2	14.2	13.5	13.4	17.8	14.6	0.7 (0.0; 1.4)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Head & Neck cancer incidence trends: by tumour stage

2.2.3. Head & Neck cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
I	N	390	490	428	489	450			162	210	197	238	203		
	CR	7.0	8.7	7.6	8.6	7.9			2.8	3.6	3.4	4.1	3.5		
	ESR2013	7.5	9.2	8.0	9.0	8.1	2.0 (1.1; 2.9)	2004-2022	2.7	3.5	3.3	3.9	3.4	5.7 (4.5; 6.8)	2004-2022
													10.0 (6.8; 13.2)	2004-2011	
													0.9 (-3.5; 5.6)	2012-2015	
													4.2 (1.2; 7.3)	2016-2022	
II	N	269	290	257	299	311			123	114	103	126	132		
	CR	4.8	5.2	4.5	5.3	5.4			2.1	2.0	1.8	2.2	2.2		
	ESR2013	5.1	5.5	4.7	5.5	5.7	1.1 (0.4; 1.8)	2004-2022	2.1	1.9	1.7	2.1	2.2	3.1 (2.3; 3.8)	2004-2022
III	N	325	298	318	305	320			133	99	111	142	118		
	CR	5.8	5.3	5.6	5.4	5.6			2.3	1.7	1.9	2.4	2.0		
	ESR2013	6.2	5.6	5.9	5.6	5.8	0.4 (-0.3; 1.1)	2004-2022	2.2	1.6	1.9	2.3	1.9	3.0 (2.0; 4.1)	2004-2022
IV	N	836	840	742	723	732			281	238	241	277	275		
	CR	14.9	14.9	13.1	12.7	12.8			4.9	4.1	4.1	4.7	4.7		
	ESR2013	15.7	15.6	13.6	13.2	13.2	-0.1 (-0.5; 0.3)	2004-2022	4.7	3.9	3.9	4.5	4.4	2.2 (1.5; 3.0)	2004-2022
							2.1 (1.3; 3.0)	2004-2014						5.0 (3.5; 6.5)	2004-2014
						-2.8 (-3.8; -1.7)	2015-2022						-1.1 (-2.9; 0.7)	2015-2022	
X/NA	N	176	158	91	136	130			61	52	59	55	50		
	CR	3.1	2.8	1.6	2.4	2.3			1.1	0.9	1.0	0.9	0.9		
	ESR2013	3.4	3.0	1.7	2.4	2.4	-10.2 (-11.3; -9.0)	2004-2022	1.0	0.9	1.0	0.9	0.8	-8.9 (-9.6; -8.2)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Head & Neck cancer incidence trends: by age group

2.3.4. Head & Neck cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
15-59	N	953	880	835	897	856	847	742	816	801	780	716	701	687	655	626	633	530	545	495		
	CR	29.8	27.4	25.9	27.7	26.3	25.9	22.6	24.7	24.1	23.5	21.5	21.1	20.6	19.6	18.8	19.0	15.9	16.3	14.8		
	ESR2013	31.8	29.0	26.9	28.8	27.3	26.7	23.2	25.2	24.4	23.6	21.4	20.8	20.2	19.2	18.3	18.4	15.4	15.9	14.4	-3.9 (-4.3; -3.6)	2004-2022
60-74	N	722	706	685	809	795	796	765	896	865	895	958	921	1,001	1,014	1,017	1,046	932	1,022	1,029		
	CR	106.1	103.1	99.7	115.6	111.6	109.5	103.2	118.5	112.4	114.2	120.2	113.3	120.2	118.4	115.7	116.4	101.6	109.4	108.8		
	ESR2013	106.4	103.2	99.7	114.9	110.3	109.8	103.0	118.2	111.8	113.2	118.6	112.8	120.3	118.1	115.9	116.4	102.0	109.7	108.8	0.2 (-0.2; 0.6)	2004-2022
75+	N	275	269	259	274	303	324	328	312	299	321	342	338	323	337	352	395	374	384	418		
	CR	93.8	88.9	82.5	84.1	90.0	93.8	92.6	86.4	81.0	85.4	89.2	86.3	81.8	85.4	88.6	97.8	90.4	92.3	96.9		
	ESR2013	92.8	87.8	78.1	80.9	87.7	92.7	89.8	85.6	81.7	84.1	88.7	86.2	79.8	84.0	89.1	97.3	90.6	92.4	96.8	0.4 (-0.1; 0.9)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.5. Head & Neck cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
15-59	N	245	236	240	254	257	275	257	262	270	232	251	249	197	213	217	206	196	238	213			
	CR	7.8	7.5	7.6	8.0	8.0	8.5	7.9	8.0	8.3	7.1	7.6	7.6	6.0	6.5	6.6	6.3	6.0	7.2	6.5			
	ESR2013	8.1	7.8	7.8	8.2	8.2	8.7	8.1	8.1	8.3	7.1	7.6	7.5	5.9	6.3	6.4	6.1	5.9	7.1	6.3	-1.8 (-2.5; -1.1)	2004-2022	
60-74	N	187	197	185	177	196	237	224	250	285	271	294	325	325	310	342	322	325	389	366			
	CR	24.1	25.4	24.0	22.7	24.9	29.6	27.7	30.4	34.2	32.0	34.3	37.3	36.4	33.8	36.4	33.6	33.3	39.1	36.4			
	ESR2013	24.1	25.6	24.3	22.7	24.8	29.7	27.6	30.3	33.9	31.9	34.1	37.2	36.4	33.8	36.3	33.6	33.2	39.2	36.5	2.6 (2.0; 3.2)	2004-2022	
																					4.1 (3.0; 5.1)	2004-2015	
																						0.2 (-1.4; 2.0)	2016-2022
75+	N	124	127	104	114	133	122	134	152	138	147	142	163	173	180	199	184	187	209	198			
	CR	23.9	23.9	19.1	20.5	23.3	21.1	22.8	25.6	23.0	24.3	23.3	26.4	28.1	29.4	32.6	30.0	30.1	33.8	31.2			
	ESR2013	24.3	23.9	19.1	20.2	23.5	21.4	23.2	25.5	22.8	24.1	23.6	26.1	28.0	29.7	33.6	30.8	31.4	34.7	32.7	2.6 (1.7; 3.4)	2004-2022	
																					0.0 (-2.8; 2.9)	2004-2010	
																					3.2 (-0.4; 7.1)	2011-2014	
																					4.2 (2.1; 6.2)	2015-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



3.1. Head & Neck cancer prevalence: by region

3.1.1. *Head & Neck cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	N	1,677	6,132	9,527	11,588	667	2,571	3,994	4,934
	CR	29.1	106.4	165.4	201	11.2	43.3	67.3	83
	ESR2013	29.8	109.4	170.6	208.3	10.8	41.4	64.1	79.0
Brussels	N	132	458	729	880	51	214	342	430
	CR	21.7	75.3	119.8	144.7	8.1	33.8	54.0	67.9
	ESR2013	30.2	107.8	175.8	215.4	10.3	42.6	67.8	84.7
Flanders	N	971	3,587	5,600	6,832	386	1,421	2,206	2,695
	CR	29.0	107.0	167.0	203.8	11.3	41.5	64.5	78.7
	ESR2013	28.1	104.2	162.9	199.1	10.4	38.1	58.9	71.8
Wallonia	N	574	2,087	3,198	3,876	230	936	1,446	1,809
	CR	31.9	115.9	177.6	215.2	12.2	49.8	76.9	96.2
	ESR2013	32.7	119.0	183.6	224.1	11.7	47.3	72.7	90.7



4.1. Head & Neck cancer survival: by region

4.1.1. *Head & Neck cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022*

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total		25,832	79.9% (79.4%; 80.4%)	63.7% (63.0%; 64.4%)	56.1% (55.4%; 56.9%)	42.2% (40.2%; 44.2%)
Males						
Belgium	All ages	18,871	79.7% (79.1%; 80.3%)	62.4% (61.6%; 63.2%)	54.4% (53.5%; 55.4%)	39.8% (37.9%; 41.8%)
	15-59	6,107	84.8% (83.9%; 85.8%)	66.6% (65.4%; 67.9%)	57.8% (56.4%; 59.2%)	45.3% (43.4%; 47.2%)
	60-74	9,388	78.8% (77.9%; 79.6%)	61.5% (60.4%; 62.6%)	53.1% (51.9%; 54.4%)	37.4% (35.4%; 39.5%)
	75+	3,492	73.1% (71.4%; 74.8%)	57.3% (55.0%; 59.6%)	52.0% (49.0%; 55.1%)	35.5% (27.6%; 45.7%)
Brussels	All ages	1,506	77.2% (75.0%; 79.5%)	60.0% (57.2%; 62.9%)	51.9% (48.7%; 55.2%)	39.7% (34.3%; 45.9%)
	15-59	548	83.6% (80.4%; 86.8%)	66.4% (62.4%; 70.7%)	59.0% (54.5%; 63.8%)	47.5% (41.4%; 54.6%)
	60-74	676	74.2% (70.9%; 77.7%)	55.0% (51.1%; 59.2%)	45.5% (41.3%; 50.2%)	31.8% (25.4%; 39.8%)
	75+	284	72.3% (66.6%; 78.5%)	59.5% (52.1%; 67.9%)	53.6% (44.4%; 64.7%)	44.0% (28.1%; 68.9%)
Flanders	All ages	10,561	81.4% (80.6%; 82.2%)	65.7% (64.7%; 66.8%)	58.3% (57.0%; 59.6%)	43.9% (41.0%; 47.0%)
	15-59	3,091	86.6% (85.4%; 87.8%)	70.9% (69.3%; 72.6%)	62.6% (60.7%; 64.5%)	51.2% (48.6%; 53.9%)
	60-74	5,293	80.8% (79.7%; 81.9%)	64.6% (63.1%; 66.0%)	56.9% (55.2%; 58.6%)	42.5% (39.8%; 45.5%)
	75+	2,245	75.5% (73.5%; 77.6%)	61.1% (58.3%; 64.1%)	55.3% (51.5%; 59.5%)	35.2% (25.1%; 49.3%)
Wallonia	All ages	6,807	77.6% (76.6%; 78.7%)	57.7% (56.5%; 59.1%)	49.1% (47.6%; 50.5%)	33.6% (31.4%; 36.0%)

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-59	2,469	83.0% (81.5%; 84.5%)	61.3% (59.4%; 63.4%)	51.5% (49.4%; 53.7%)	37.6% (34.8%; 40.6%)
	60-74	3,420	76.5% (75.0%; 78.0%)	58.0% (56.2%; 59.8%)	48.8% (46.8%; 50.8%)	30.3% (27.3%; 33.6%)
	75+	964	67.7% (64.4%; 71.0%)	47.4% (43.5%; 51.7%)	43.5% (38.8%; 48.8%)	33.8% (23.5%; 48.5%)
Females						
Belgium	All ages	6,961	80.6% (79.6%; 81.6%)	67.2% (65.9%; 68.4%)	60.8% (59.4%; 62.3%)	48.6% (43.7%; 54.0%)
	15-59	2,128	89.0% (87.6%; 90.3%)	76.9% (75.1%; 78.8%)	70.4% (68.3%; 72.6%)	58.4% (55.4%; 61.7%)
	60-74	3,137	81.5% (80.1%; 82.9%)	66.5% (64.7%; 68.3%)	58.6% (56.6%; 60.6%)	45.0% (41.9%; 48.4%)
	75+	1,733	68.9% (66.4%; 71.4%)	56.6% (53.6%; 59.8%)	53.0% (49.2%; 57.0%)	42.7% (28.4%; 64.2%)
Brussels	All ages	606	80.0% (76.7%; 83.5%)	65.2% (61.1%; 69.7%)	59.3% (54.6%; 64.4%)	40.7% (33.1%; 50.2%)
	15-59	206	91.8% (88.1%; 95.7%)	79.1% (73.5%; 85.1%)	75.7% (69.6%; 82.3%)	70.6% (61.0%; 81.7%)
	60-74	253	80.4% (75.5%; 85.6%)	64.2% (58.2%; 70.9%)	58.0% (51.4%; 65.4%)	39.5% (30.0%; 52.0%)
	75+	149	63.6% (55.7%; 72.7%)	48.7% (39.5%; 60.1%)	39.4% (28.8%; 53.8%)	8.0% (2.3%; 27.1%)
Flanders	All ages	3,714	82.2% (80.9%; 83.6%)	69.9% (68.2%; 71.7%)	63.4% (61.4%; 65.5%)	54.2% (49.8%; 59.0%)
	15-59	1,062	90.9% (89.2%; 92.7%)	80.5% (78.1%; 83.1%)	73.9% (71.0%; 76.9%)	61.8% (57.5%; 66.5%)
	60-74	1,639	83.7% (81.8%; 85.5%)	69.7% (67.3%; 72.1%)	62.2% (59.5%; 65.1%)	48.5% (43.8%; 53.7%)
	75+	1,038	71.3% (68.2%; 74.5%)	59.4% (55.5%; 63.5%)	54.4% (49.5%; 59.8%)	55.3% (41.6%; 73.5%)
Wallonia	All ages	2,641	78.5% (76.8%; 80.1%)	63.7% (61.7%; 65.8%)	57.5% (55.2%; 59.8%)	42.8% (33.8%; 54.2%)
	15-59	860	85.9% (83.6%; 88.3%)	71.9% (68.8%; 75.1%)	64.8% (61.4%; 68.4%)	51.4% (46.7%; 56.5%)
	60-74	1,245	78.9% (76.7%; 81.3%)	62.7% (59.9%; 65.6%)	53.9% (50.8%; 57.2%)	41.4% (37.2%; 46.2%)
	75+	546	65.7% (61.4%; 70.2%)	53.4% (48.3%; 59.1%)	53.9% (47.6%; 61.1%)	35.7% (14.7%; 86.4%)

4.2. Head & Neck cancer survival: by sub-location and tumour stage

4.2.2. Head & Neck cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	25,832	79.9% (79.4%; 80.4%)	69.9% (69.3%; 70.5%)	63.7% (63.0%; 64.4%)	59.3% (58.6%; 60.1%)	56.1% (55.4%; 56.9%)	42.2% (40.2%; 44.2%)
Males								
Head & Neck (C00-C14, C30-C32)	All	18,871	79.7% (79.1%; 80.3%)	69.1% (68.4%; 69.9%)	62.4% (61.6%; 63.2%)	57.8% (57.0%; 58.7%)	54.4% (53.5%; 55.4%)	39.8% (37.9%; 41.8%)
	I	3,431	95.8% (94.9%; 96.7%)	91.2% (90.0%; 92.5%)	87.4% (85.8%; 89.0%)	84.7% (82.8%; 86.7%)	82.1% (79.8%; 84.4%)	62.1% (54.5%; 70.8%)
	II	2,616	90.1% (88.8%; 91.4%)	81.7% (80.0%; 83.5%)	74.2% (72.2%; 76.3%)	69.1% (66.8%; 71.4%)	65.7% (63.2%; 68.2%)	48.2% (43.6%; 53.3%)
	III	2,814	82.1% (80.6%; 83.7%)	72.2% (70.4%; 74.0%)	65.3% (63.3%; 67.4%)	60.1% (57.9%; 62.4%)	56.2% (53.7%; 58.7%)	37.7% (33.4%; 42.6%)
	IV	7,579	68.0% (66.9%; 69.1%)	53.0% (51.8%; 54.2%)	44.7% (43.5%; 46.0%)	39.9% (38.7%; 41.2%)	35.7% (34.5%; 37.0%)	25.1% (23.3%; 27.1%)
	X/NA	3,055	78.8% (77.3%; 80.4%)	68.7% (66.9%; 70.5%)	62.5% (60.5%; 64.5%)	57.5% (55.4%; 59.6%)	55.4% (53.2%; 57.6%)	41.9% (38.3%; 46.0%)
Lip (C00)	All	328	95.3% (92.1%; 98.6%)	90.0% (85.4%; 94.9%)	86.2% (80.5%; 92.2%)	84.3% (77.7%; 91.5%)	84.1% (76.7%; 92.2%)	75.9% (52.4%; 109.8%)
	I	136	99.6% (95.7%; 103.6%)	97.9% (91.7%; 104.5%)	95.7% (87.5%; 104.6%)	95.8% (86.3%; 106.4%)	93.2% (81.4%; 106.7%)	55.5% (22.8%; 135.0%)
	II	31	N<50	N<50	N<50	N<50	N<50	N<50
	III	19	N<50	N<50	N<50	N<50	N<50	N<50
	IV	18	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	124	97.1% (92.4%; 102.1%)	94.5% (87.8%; 101.8%)	88.7% (80.1%; 98.2%)	83.9% (73.4%; 96.0%)	84.0% (72.7%; 97.1%)	89.9% (69.7%; 115.9%)
Oral cavity (C02-C05.0, C06)	All	4,305	80.4% (79.2%; 81.7%)	69.4% (67.9%; 70.9%)	62.0% (60.4%; 63.7%)	57.0% (55.3%; 58.8%)	53.4% (51.5%; 55.3%)	38.0% (34.7%; 41.7%)
	I	780	95.3% (93.5%; 97.1%)	88.1% (85.4%; 90.9%)	83.4% (80.2%; 86.8%)	78.9% (75.2%; 82.8%)	75.0% (70.7%; 79.4%)	60.6% (53.3%; 68.8%)
	II	665	90.3% (87.8%; 92.9%)	81.0% (77.7%; 84.5%)	70.7% (66.8%; 74.8%)	65.4% (61.1%; 70.0%)	61.5% (56.8%; 66.5%)	43.9% (35.5%; 54.2%)
	III	598	81.0% (77.8%; 84.4%)	70.0% (66.1%; 74.1%)	62.4% (58.1%; 66.9%)	55.0% (50.3%; 60.1%)	50.9% (45.8%; 56.5%)	33.3% (25.1%; 44.2%)

Net Survival Probability, 2013-2022								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IV	1,624	69.2% (66.9%; 71.6%)	54.5% (52.0%; 57.1%)	46.4% (43.8%; 49.1%)	41.6% (38.9%; 44.4%)	37.4% (34.6%; 40.4%)	25.6% (21.2%; 30.9%)
	X/NA	699	80.4% (77.3%; 83.6%)	71.4% (67.8%; 75.2%)	65.6% (61.7%; 69.7%)	60.8% (56.6%; 65.3%)	59.1% (54.6%; 63.9%)	40.3% (33.0%; 49.3%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	8,060	74.7% (73.8%; 75.7%)	61.9% (60.7%; 63.0%)	54.3% (53.1%; 55.5%)	49.3% (48.0%; 50.5%)	45.2% (43.9%; 46.5%)	32.2% (30.3%; 34.3%)
	I	851	92.3% (90.3%; 94.4%)	83.2% (80.4%; 86.1%)	77.3% (74.0%; 80.8%)	71.5% (67.7%; 75.6%)	67.7% (63.4%; 72.4%)	47.7% (39.3%; 57.8%)
	II	957	87.7% (85.5%; 90.0%)	78.1% (75.2%; 81.1%)	70.0% (66.7%; 73.6%)	64.7% (61.1%; 68.6%)	59.8% (55.9%; 64.1%)	41.3% (34.7%; 49.2%)
	III	1,291	82.1% (79.9%; 84.3%)	71.6% (69.0%; 74.3%)	65.5% (62.6%; 68.5%)	61.1% (58.0%; 64.4%)	57.8% (54.5%; 61.3%)	41.2% (35.2%; 48.3%)
	IV	4,273	66.8% (65.3%; 68.3%)	51.6% (50.1%; 53.2%)	43.2% (41.7%; 44.8%)	38.7% (37.1%; 40.3%)	34.4% (32.8%; 36.1%)	24.9% (22.7%; 27.2%)
	X/NA	845	70.3% (67.2%; 73.5%)	57.2% (53.8%; 60.8%)	50.2% (46.7%; 53.9%)	43.8% (40.2%; 47.6%)	40.9% (37.3%; 44.8%)	28.7% (24.3%; 33.9%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	5,350	77.1% (75.9%; 78.3%)	64.8% (63.4%; 66.2%)	57.8% (56.4%; 59.3%)	53.0% (51.4%; 54.5%)	48.6% (47.0%; 50.3%)	35.3% (32.7%; 38.1%)
	I	718	92.7% (90.5%; 94.9%)	84.2% (81.2%; 87.3%)	79.4% (75.8%; 83.1%)	73.7% (69.4%; 78.1%)	70.3% (65.4%; 75.4%)	50.3% (40.3%; 62.8%)
	II	689	90.2% (87.7%; 92.7%)	80.7% (77.4%; 84.1%)	72.6% (68.7%; 76.7%)	66.4% (62.1%; 71.0%)	61.3% (56.6%; 66.4%)	44.6% (36.0%; 55.2%)
	III	821	82.0% (79.2%; 84.8%)	71.3% (68.1%; 74.8%)	65.8% (62.2%; 69.5%)	62.3% (58.5%; 66.4%)	57.6% (53.5%; 62.0%)	40.6% (31.7%; 52.0%)
	IV	2,540	68.5% (66.6%; 70.4%)	53.9% (51.9%; 55.9%)	46.4% (44.3%; 48.5%)	42.2% (40.1%; 44.4%)	37.7% (35.5%; 39.9%)	28.0% (25.1%; 31.2%)
	X/NA	629	73.0% (69.5%; 76.7%)	60.3% (56.4%; 64.5%)	52.9% (48.9%; 57.3%)	46.2% (42.1%; 50.7%)	44.1% (39.9%; 48.7%)	30.8% (25.8%; 36.9%)
Nasopharynx C11	All	458	85.6% (82.3%; 89.0%)	77.7% (73.8%; 81.9%)	72.2% (67.9%; 76.8%)	69.5% (65.0%; 74.5%)	67.2% (62.3%; 72.4%)	57.2% (50.4%; 65.0%)
	I	29	N<50	N<50	N<50	N<50	N<50	N<50
	II	87	93.1% (87.5%; 99.2%)	90.8% (84.1%; 98.1%)	87.6% (79.6%; 96.5%)	84.8% (75.5%; 95.3%)	86.1% (76.7%; 96.8%)	67.1% (51.1%; 88.1%)
	III	143	90.3% (85.3%; 95.6%)	87.5% (81.9%; 93.6%)	81.9% (75.2%; 89.2%)	79.2% (72.1%; 87.1%)	80.1% (72.9%; 88.1%)	74.5% (64.8%; 85.7%)
	IV	156	77.7% (71.3%; 84.6%)	68.1% (60.9%; 76.2%)	59.9% (52.3%; 68.6%)	57.9% (50.0%; 67.0%)	52.9% (44.5%; 62.9%)	41.0% (29.2%; 57.6%)
	X/NA	43	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Hypopharynx C12-C13	All	2,395	67.1% (65.1%; 69.0%)	51.6% (49.5%; 53.7%)	42.0% (40.0%; 44.2%)	36.4% (34.3%; 38.7%)	32.5% (30.4%; 34.8%)	20.1% (17.4%; 23.2%)
	I	106	89.7% (83.5%; 96.3%)	78.0% (69.7%; 87.2%)	63.9% (54.3%; 75.1%)	55.7% (45.8%; 67.7%)	51.2% (41.0%; 63.9%)	32.0% (19.8%; 51.7%)
	II	187	75.0% (68.7%; 81.8%)	61.1% (54.0%; 69.2%)	50.7% (43.3%; 59.4%)	47.4% (39.7%; 56.5%)	39.3% (31.5%; 49.1%)	20.3% (12.0%; 34.4%)
	III	328	78.8% (74.3%; 83.6%)	65.3% (60.0%; 71.1%)	57.7% (52.0%; 64.1%)	50.4% (44.1%; 57.6%)	48.7% (42.2%; 56.2%)	28.2% (20.6%; 38.6%)
	IV	1,597	63.0% (60.6%; 65.4%)	46.3% (43.8%; 48.9%)	36.4% (33.9%; 39.0%)	31.0% (28.6%; 33.7%)	27.2% (24.8%; 29.9%)	17.7% (14.8%; 21.3%)
	X/NA	180	60.4% (53.6%; 68.2%)	48.1% (41.1%; 56.2%)	41.0% (34.1%; 49.3%)	35.7% (28.8%; 44.1%)	31.4% (24.7%; 40.0%)	21.3% (13.6%; 33.5%)
Larynx (C32)	All	4,813	85.4% (84.3%; 86.5%)	78.4% (77.1%; 79.8%)	73.0% (71.5%; 74.6%)	68.7% (66.9%; 70.4%)	65.8% (63.9%; 67.8%)	46.6% (42.1%; 51.6%)
	I	1,540	97.6% (96.4%; 98.8%)	96.3% (94.6%; 98.0%)	93.5% (91.2%; 95.8%)	91.9% (89.0%; 95.0%)	90.5% (87.1%; 94.1%)	68.7% (57.1%; 82.6%)
	II	765	90.4% (88.0%; 92.8%)	83.1% (80.0%; 86.3%)	77.7% (74.1%; 81.5%)	71.9% (67.8%; 76.2%)	68.9% (64.4%; 73.7%)	50.2% (42.3%; 59.7%)
	III	733	81.5% (78.5%; 84.6%)	72.5% (69.0%; 76.2%)	65.2% (61.3%; 69.4%)	59.1% (54.8%; 63.7%)	54.6% (50.1%; 59.6%)	31.8% (24.0%; 42.1%)
	IV	1,164	70.4% (67.7%; 73.2%)	56.7% (53.7%; 59.8%)	49.1% (46.0%; 52.4%)	43.3% (40.1%; 46.8%)	39.3% (35.9%; 42.9%)	23.9% (19.7%; 29.0%)
	X/NA	611	82.0% (78.8%; 85.4%)	75.9% (72.1%; 79.9%)	70.4% (66.1%; 74.9%)	65.6% (60.9%; 70.7%)	63.2% (58.2%; 68.6%)	45.4% (37.4%; 55.1%)
Nasal cavity and paranasal sinuses (C30- C31)	All	959	81.9% (79.3%; 84.7%)	69.5% (66.3%; 72.9%)	63.7% (60.2%; 67.6%)	60.0% (56.1%; 64.1%)	59.2% (55.0%; 63.6%)	49.8% (40.7%; 60.9%)
	I	87	94.8% (89.2%; 100.9%)	87.2% (78.8%; 96.6%)	82.9% (72.8%; 94.3%)	83.0% (72.3%; 95.3%)	85.3% (74.3%; 98.0%)	75.6% (53.1%; 107.7%)
	II	112	99.7% (95.7%; 103.7%)	96.7% (90.4%; 103.5%)	93.2% (84.4%; 102.9%)	88.3% (77.1%; 101.1%)	93.0% (80.8%; 107.0%)	88.0% (59.3%; 130.6%)
	III	102	87.7% (80.7%; 95.4%)	79.6% (70.6%; 89.7%)	70.1% (59.2%; 83.0%)	67.2% (55.4%; 81.5%)	67.4% (54.9%; 82.7%)	45.7% (26.5%; 78.6%)
	IV	312	68.6% (63.4%; 74.3%)	51.5% (45.8%; 58.0%)	43.6% (37.8%; 50.4%)	40.5% (34.6%; 47.6%)	39.1% (32.9%; 46.5%)	32.9% (21.4%; 50.6%)
	X/NA	348	83.4% (79.1%; 87.8%)	69.6% (64.3%; 75.3%)	65.5% (59.8%; 71.8%)	60.4% (54.2%; 67.3%)	57.7% (51.1%; 65.2%)	48.7% (34.9%; 67.9%)
Salivary glands (C07-C08)	All	813	85.7% (83.0%; 88.5%)	75.0% (71.6%; 78.6%)	67.7% (63.7%; 71.9%)	65.6% (61.3%; 70.2%)	61.0% (55.7%; 66.8%)	51.2% (42.1%; 62.3%)
	I	73	102.2% (99.5%; 105.0%)	102.1% (96.3%; 108.1%)	106.5% (99.8%; 113.8%)	115.5% (108.2%; 123.3%)	105.3% (85.9%; 129.0%)	84.1% (44.6%; 158.7%)
	II	106	95.2% (90.0%; 100.8%)	91.8% (84.8%; 99.4%)	83.9% (74.7%; 94.3%)	84.7% (74.9%; 95.9%)	80.3% (68.3%; 94.5%)	58.5% (39.0%; 87.8%)

Net Survival Probability, 2013-2022								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	82	89.2% (81.2%; 98.0%)	84.8% (74.7%; 96.3%)	77.6% (64.5%; 93.5%)	76.1% (61.5%; 94.1%)	60.6% (38.5%; 95.2%)	45.3% (24.5%; 83.6%)
	IV	220	68.0% (61.6%; 75.0%)	49.5% (42.6%; 57.5%)	41.3% (34.3%; 49.8%)	33.6% (26.5%; 42.7%)	27.0% (19.6%; 37.4%)	28.2% (18.2%; 43.7%)
	X/NA	332	90.0% (86.2%; 93.9%)	78.1% (73.0%; 83.6%)	68.9% (63.0%; 75.4%)	66.8% (60.6%; 73.7%)	66.0% (59.5%; 73.2%)	57.8% (46.3%; 72.0%)
Other and ill-defined sites (C14)	All	147	53.6% (46.0%; 62.5%)	42.8% (35.3%; 52.0%)	36.5% (29.1%; 45.7%)	30.3% (23.2%; 39.5%)	28.9% (21.8%; 38.4%)	8.4% (3.0%; 23.4%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	146	53.3% (45.7%; 62.2%)	42.4% (34.9%; 51.6%)	35.9% (28.6%; 45.2%)	29.7% (22.7%; 38.9%)	28.3% (21.2%; 37.7%)	8.7% (3.1%; 24.1%)
Females								
Head & Neck (C00-C14, C30- C32)	All	6,961	80.6% (79.6%; 81.6%)	71.9% (70.7%; 73.1%)	67.2% (65.9%; 68.4%)	63.4% (62.0%; 64.8%)	60.8% (59.4%; 62.3%)	48.6% (43.7%; 54.0%)
	I	1,364	95.4% (94.1%; 96.8%)	93.0% (91.2%; 94.8%)	89.5% (87.3%; 91.8%)	85.9% (83.2%; 88.7%)	84.7% (81.7%; 87.8%)	83.0% (75.2%; 91.6%)
	II	1,052	91.6% (89.7%; 93.6%)	84.5% (82.0%; 87.1%)	80.7% (77.8%; 83.8%)	76.4% (73.0%; 80.0%)	75.5% (71.8%; 79.4%)	53.2% (32.9%; 86.0%)
	III	974	82.1% (79.6%; 84.7%)	72.3% (69.3%; 75.4%)	66.3% (63.0%; 69.8%)	62.2% (58.6%; 66.0%)	58.7% (54.9%; 62.8%)	49.0% (40.7%; 59.1%)
	IV	2,428	65.4% (63.4%; 67.4%)	52.4% (50.4%; 54.6%)	46.4% (44.3%; 48.6%)	42.8% (40.6%; 45.1%)	38.8% (36.6%; 41.2%)	25.5% (21.5%; 30.1%)
	X/NA	1,360	82.5% (80.4%; 84.8%)	74.4% (71.9%; 77.0%)	70.3% (67.5%; 73.2%)	66.1% (63.1%; 69.3%)	64.0% (60.8%; 67.4%)	53.9% (48.3%; 60.2%)
Lip (C00)	All	166	97.2% (92.8%; 101.8%)	90.0% (83.2%; 97.4%)	86.4% (77.9%; 95.9%)	82.3% (72.2%; 93.9%)	83.6% (72.2%; 96.9%)	86.7% (59.8%; 125.6%)
	I	64	101.4% (96.9%; 106.1%)	102.0% (94.2%; 110.4%)	93.0% (80.3%; 107.6%)	88.9% (74.4%; 106.2%)	94.0% (78.6%; 112.4%)	133.8% (93.9%; 190.5%)
	II	23	N<50	N<50	N<50	N<50	N<50	N<50
	III	10	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	60	98.0% (90.5%; 106.0%)	87.2% (75.3%; 101.1%)	86.1% (72.2%; 102.7%)	80.0% (63.2%; 101.1%)	79.6% (60.8%; 104.1%)	59.2% (28.9%; 121.0%)

Net Survival Probability, 2013-2022								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Oral cavity (C02-C05.0, C06)	All	2,409	80.1% (78.4%; 81.9%)	70.2% (68.2%; 72.2%)	65.8% (63.6%; 68.0%)	62.1% (59.8%; 64.5%)	59.8% (57.3%; 62.4%)	46.9% (36.3%; 60.6%)
	I	521	96.0% (93.9%; 98.2%)	92.2% (89.3%; 95.2%)	90.0% (86.4%; 93.7%)	85.7% (81.4%; 90.2%)	82.3% (77.4%; 87.5%)	73.0% (60.6%; 88.0%)
	II	390	90.8% (87.5%; 94.2%)	85.3% (81.0%; 89.7%)	79.8% (74.7%; 85.2%)	75.7% (69.6%; 82.3%)	75.6% (69.1%; 82.7%)	55.4% (25.0%; 122.6%)
	III	290	82.1% (77.5%; 87.0%)	69.3% (63.7%; 75.3%)	64.8% (58.8%; 71.4%)	58.5% (51.8%; 66.1%)	58.3% (51.2%; 66.4%)	56.5% (44.1%; 72.3%)
	IV	813	62.7% (59.3%; 66.3%)	47.7% (44.2%; 51.5%)	42.6% (39.0%; 46.5%)	40.0% (36.3%; 44.1%)	36.1% (32.3%; 40.4%)	23.7% (16.5%; 34.1%)
	X/NA	441	82.8% (79.0%; 86.7%)	73.3% (68.8%; 78.1%)	68.1% (63.2%; 73.4%)	64.4% (59.3%; 70.1%)	62.5% (56.9%; 68.6%)	54.9% (45.8%; 65.9%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	2,667	77.0% (75.3%; 78.6%)	66.9% (65.0%; 68.8%)	61.2% (59.2%; 63.3%)	56.6% (54.5%; 58.8%)	53.2% (51.0%; 55.5%)	38.1% (34.4%; 42.1%)
	I	380	91.0% (88.0%; 94.2%)	87.7% (84.0%; 91.5%)	81.1% (76.5%; 86.0%)	76.0% (70.7%; 81.8%)	73.8% (67.9%; 80.2%)	56.4% (44.1%; 72.2%)
	II	403	90.3% (87.2%; 93.5%)	80.9% (76.8%; 85.2%)	78.1% (73.6%; 82.9%)	72.7% (67.5%; 78.2%)	70.3% (64.8%; 76.2%)	51.2% (41.9%; 62.7%)
	III	450	80.5% (76.7%; 84.4%)	71.6% (67.3%; 76.2%)	64.8% (60.1%; 69.8%)	60.5% (55.5%; 65.9%)	57.4% (52.1%; 63.2%)	44.2% (35.1%; 55.6%)
	IV	1,168	66.7% (64.0%; 69.5%)	53.9% (51.0%; 56.9%)	46.6% (43.7%; 49.8%)	42.7% (39.7%; 45.9%)	38.4% (35.4%; 41.7%)	27.4% (22.9%; 32.8%)
	X/NA	311	76.5% (71.8%; 81.6%)	66.1% (60.8%; 71.9%)	64.3% (58.8%; 70.3%)	57.2% (51.3%; 63.8%)	54.7% (48.6%; 61.5%)	35.6% (28.0%; 45.1%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	2,043	78.9% (77.1%; 80.8%)	68.5% (66.4%; 70.6%)	63.5% (61.2%; 65.8%)	59.2% (56.8%; 61.7%)	56.0% (53.5%; 58.6%)	40.7% (36.4%; 45.5%)
	I	329	91.9% (88.8%; 95.2%)	88.3% (84.4%; 92.3%)	82.5% (77.6%; 87.7%)	78.0% (72.4%; 84.1%)	75.8% (69.6%; 82.6%)	58.5% (45.0%; 76.1%)
	II	306	90.3% (86.7%; 93.9%)	80.7% (76.0%; 85.7%)	77.6% (72.4%; 83.2%)	71.4% (65.4%; 77.9%)	68.6% (62.2%; 75.7%)	46.5% (36.5%; 59.3%)
	III	326	81.4% (77.1%; 86.0%)	72.8% (67.8%; 78.2%)	67.4% (61.9%; 73.3%)	63.8% (58.1%; 70.2%)	60.4% (54.2%; 67.2%)	45.8% (34.6%; 60.6%)
	IV	843	69.2% (66.1%; 72.4%)	55.6% (52.2%; 59.1%)	48.6% (45.2%; 52.3%)	44.7% (41.2%; 48.5%)	41.0% (37.5%; 44.9%)	30.8% (25.2%; 37.6%)
	X/NA	260	77.5% (72.4%; 83.0%)	66.0% (60.2%; 72.4%)	65.8% (59.9%; 72.4%)	61.3% (54.9%; 68.3%)	59.7% (53.2%; 67.0%)	40.2% (31.9%; 50.6%)
Nasopharynx C11	All	182	86.2% (81.2%; 91.6%)	82.2% (76.5%; 88.3%)	77.3% (70.9%; 84.3%)	72.3% (65.1%; 80.4%)	70.8% (63.3%; 79.2%)	61.0% (49.1%; 75.8%)

Net Survival Probability, 2013-2022								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	10	N<50	N<50	N<50	N<50	N<50	N<50
	II	47	N<50	N<50	N<50	N<50	N<50	N<50
	III	48	N<50	N<50	N<50	N<50	N<50	N<50
	IV	61	72.5% (62.0%; 84.9%)	69.7% (58.8%; 82.6%)	64.3% (52.9%; 78.3%)	64.8% (53.3%; 78.9%)	62.1% (50.0%; 77.1%)	51.9% (36.9%; 73.0%)
	X/NA	16	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	All	470	65.2% (60.9%; 69.7%)	54.3% (49.8%; 59.2%)	44.9% (40.3%; 50.0%)	37.8% (33.2%; 43.1%)	31.9% (27.2%; 37.3%)	17.4% (12.0%; 25.0%)
	I	42	N<50	N<50	N<50	N<50	N<50	N<50
	II	51	81.4% (70.9%; 93.5%)	65.5% (53.1%; 80.9%)	63.9% (51.2%; 79.7%)	61.2% (47.9%; 78.2%)	57.6% (43.5%; 76.2%)	55.7% (38.8%; 79.8%)
	III	77	72.4% (62.9%; 83.3%)	62.6% (52.4%; 74.9%)	47.0% (36.5%; 60.6%)	36.1% (25.6%; 50.8%)	34.9% (24.4%; 50.0%)	22.5% (11.6%; 43.8%)
	IV	265	57.2% (51.4%; 63.6%)	44.8% (39.0%; 51.4%)	35.9% (30.2%; 42.6%)	30.8% (25.2%; 37.6%)	24.0% (18.7%; 30.9%)	10.4% (5.9%; 18.5%)
	X/NA	35	N<50	N<50	N<50	N<50	N<50	N<50
Larynx (C32)	All	874	85.1% (82.6%; 87.7%)	77.7% (74.7%; 80.8%)	71.8% (68.5%; 75.3%)	68.0% (64.4%; 71.9%)	65.4% (61.5%; 69.5%)	56.6% (50.5%; 63.5%)
	I	257	97.1% (94.3%; 99.9%)	96.4% (92.8%; 100.1%)	94.3% (89.8%; 99.0%)	92.7% (87.3%; 98.5%)	95.3% (89.6%; 101.4%)	100.5% (88.0%; 114.8%)
	II	139	90.4% (85.3%; 95.8%)	81.1% (74.4%; 88.4%)	76.9% (69.4%; 85.3%)	69.9% (61.5%; 79.6%)	65.9% (56.9%; 76.3%)	45.8% (33.5%; 62.8%)
	III	143	81.7% (75.1%; 88.8%)	71.4% (63.8%; 79.9%)	62.2% (54.0%; 71.7%)	59.7% (50.9%; 70.0%)	50.0% (40.6%; 61.7%)	37.4% (24.6%; 56.8%)
	IV	216	70.6% (64.6%; 77.1%)	56.8% (50.4%; 64.2%)	49.0% (42.3%; 56.7%)	44.4% (37.7%; 52.4%)	42.9% (36.0%; 51.1%)	25.4% (17.2%; 37.3%)
	X/NA	119	83.7% (77.0%; 91.0%)	78.4% (70.7%; 86.8%)	69.8% (61.2%; 79.7%)	65.2% (55.7%; 76.4%)	60.0% (50.1%; 71.9%)	55.8% (42.7%; 72.8%)
Nasal cavity and paranasal sinuses (C30- C31)	All	367	78.8% (74.5%; 83.4%)	70.2% (65.1%; 75.6%)	65.7% (60.3%; 71.6%)	62.4% (56.7%; 68.7%)	59.7% (53.6%; 66.6%)	52.3% (41.1%; 66.6%)
	I	47	N<50	N<50	N<50	N<50	N<50	N<50
	II	20	N<50	N<50	N<50	N<50	N<50	N<50
	III	30	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IV	115	58.7% (50.1%; 68.8%)	50.0% (41.0%; 61.0%)	44.0% (34.9%; 55.4%)	37.8% (28.7%; 49.8%)	37.0% (27.7%; 49.4%)	17.3% (8.0%; 37.3%)
	X/NA	155	83.9% (77.8%; 90.5%)	72.3% (64.8%; 80.5%)	68.9% (60.9%; 77.9%)	66.3% (57.9%; 75.9%)	61.7% (52.7%; 72.3%)	48.3% (35.1%; 66.7%)
Salivary glands (C07-C08)	All	598	89.5% (86.7%; 92.4%)	87.8% (84.5%; 91.1%)	87.1% (83.4%; 90.9%)	85.9% (81.6%; 90.5%)	84.8% (79.9%; 90.0%)	73.0% (60.8%; 87.7%)
	I	107	100.3% (98.4%; 102.1%)	99.6% (96.3%; 103.0%)	98.7% (93.7%; 103.9%)	97.4% (90.7%; 104.7%)	95.0% (85.4%; 105.7%)	112.5% (97.3%; 130.1%)
	II	85	100.0% (96.6%; 103.4%)	101.6% (97.4%; 106.0%)	102.0% (96.0%; 108.4%)	104.8% (97.7%; 112.4%)	111.2% (103.7%; 119.3%)	88.4% (58.2%; 134.3%)
	III	54	91.8% (83.6%; 100.9%)	88.6% (78.2%; 100.4%)	88.9% (77.1%; 102.6%)	88.9% (75.3%; 105.0%)	81.9% (66.6%; 100.9%)	53.9% (22.7%; 127.8%)
	IV	116	65.9% (57.2%; 76.0%)	59.7% (50.2%; 70.9%)	62.3% (52.3%; 74.2%)	59.1% (48.1%; 72.5%)	52.1% (40.1%; 67.6%)	25.9% (12.6%; 53.1%)
	X/NA	237	92.0% (88.0%; 96.1%)	91.1% (86.5%; 96.0%)	88.3% (82.8%; 94.1%)	86.8% (80.2%; 93.8%)	87.5% (80.6%; 95.1%)	82.3% (66.9%; 101.2%)
Other and ill-defined sites (C14)	All	47	N<50	N<50	N<50	N<50	N<50	N<50
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	47	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.3. Head & Neck cancer survival by sub-location, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	25,832	79.9% (79.4%; 80.4%)	69.9% (69.3%; 70.5%)	63.7% (63.0%; 64.4%)	59.3% (58.6%; 60.1%)	56.1% (55.4%; 56.9%)	42.2% (40.2%; 44.2%)
Males								
Head & Neck (C00-C14, C30-C32)	All	18,871	79.7% (79.1%; 80.3%)	69.1% (68.4%; 69.9%)	62.4% (61.6%; 63.2%)	57.8% (57.0%; 58.7%)	54.4% (53.5%; 55.4%)	39.8% (37.9%; 41.8%)
	I	2,600	97.7% (96.9%; 98.6%)	94.3% (93.0%; 95.6%)	90.3% (88.7%; 92.0%)	87.4% (85.4%; 89.5%)	84.8% (82.4%; 87.3%)	66.3% (59.7%; 73.7%)
	II	1,139	93.2% (91.5%; 95.0%)	85.3% (82.9%; 87.8%)	77.9% (75.0%; 81.0%)	73.2% (69.8%; 76.7%)	69.8% (66.1%; 73.7%)	51.6% (43.7%; 61.0%)
	III	1,136	89.3% (87.3%; 91.3%)	78.7% (76.0%; 81.4%)	71.5% (68.5%; 74.7%)	66.9% (63.6%; 70.4%)	62.8% (59.1%; 66.7%)	43.9% (37.8%; 51.0%)
	IV	2,565	80.7% (79.1%; 82.3%)	63.8% (61.8%; 65.8%)	54.6% (52.5%; 56.8%)	47.8% (45.6%; 50.1%)	43.6% (41.3%; 46.1%)	30.7% (26.9%; 34.9%)
	X/NA	11,908	73.4% (72.6%; 74.3%)	62.1% (61.2%; 63.1%)	55.3% (54.3%; 56.3%)	50.8% (49.7%; 51.9%)	47.4% (46.3%; 48.5%)	33.7% (31.5%; 36.2%)
Lip (C00)	All	328	95.3% (92.1%; 98.6%)	90.0% (85.4%; 94.9%)	86.2% (80.5%; 92.2%)	84.3% (77.7%; 91.5%)	84.1% (76.7%; 92.2%)	75.9% (52.4%; 109.8%)
	I	189	100.5% (97.5%; 103.6%)	98.8% (93.7%; 104.2%)	97.6% (91.1%; 104.5%)	95.4% (87.1%; 104.5%)	94.1% (84.3%; 105.0%)	85.0% (52.1%; 138.5%)
	II	50	95.1% (87.3%; 103.7%)	91.3% (80.9%; 103.1%)	83.9% (70.8%; 99.3%)	87.3% (73.8%; 103.4%)	89.2% (74.5%; 106.7%)	99.6% (75.3%; 131.7%)
	III	15	N<50	N<50	N<50	N<50	N<50	N<50
	IV	14	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	60	87.4% (78.1%; 97.8%)	76.0% (64.1%; 90.1%)	68.5% (54.8%; 85.7%)	66.5% (51.4%; 86.1%)	67.9% (52.0%; 88.7%)	57.9% (36.4%; 92.2%)
Oral cavity (C02-C05.0, C06)	All	4,305	80.4% (79.2%; 81.7%)	69.4% (67.9%; 70.9%)	62.0% (60.4%; 63.7%)	57.0% (55.3%; 58.8%)	53.4% (51.5%; 55.3%)	38.0% (34.7%; 41.7%)
	I	957	97.7% (96.4%; 99.0%)	93.4% (91.4%; 95.5%)	88.9% (86.3%; 91.6%)	84.8% (81.6%; 88.0%)	81.3% (77.5%; 85.2%)	58.0% (49.2%; 68.2%)
	II	567	91.5% (88.9%; 94.1%)	85.2% (81.9%; 88.7%)	77.4% (73.3%; 81.7%)	70.5% (65.7%; 75.6%)	65.8% (60.6%; 71.5%)	47.2% (38.4%; 58.2%)
	III	543	88.4% (85.5%; 91.4%)	77.7% (73.9%; 81.7%)	68.4% (64.0%; 73.0%)	63.5% (58.7%; 68.8%)	59.0% (53.7%; 64.8%)	43.0% (33.9%; 54.5%)
	IV	1,052	80.6% (78.1%; 83.1%)	64.2% (61.2%; 67.4%)	55.0% (51.8%; 58.4%)	48.0% (44.7%; 51.6%)	44.3% (40.8%; 48.1%)	30.9% (24.9%; 38.5%)

Net Survival Probability, 2013-2022								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	1,238	58.7% (55.9%; 61.6%)	44.1% (41.3%; 47.1%)	37.2% (34.4%; 40.3%)	33.5% (30.6%; 36.6%)	30.9% (28.0%; 34.1%)	21.4% (17.7%; 26.0%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	8,060	74.7% (73.8%; 75.7%)	61.9% (60.7%; 63.0%)	54.3% (53.1%; 55.5%)	49.3% (48.0%; 50.5%)	45.2% (43.9%; 46.5%)	32.2% (30.3%; 34.3%)
	I	553	95.0% (92.9%; 97.1%)	87.0% (83.8%; 90.3%)	80.2% (76.3%; 84.2%)	74.5% (70.1%; 79.2%)	70.8% (65.9%; 76.2%)	59.2% (51.4%; 68.3%)
	II	241	91.3% (87.5%; 95.4%)	78.1% (72.6%; 84.1%)	70.4% (64.1%; 77.3%)	64.7% (57.9%; 72.4%)	59.4% (52.1%; 67.7%)	48.2% (36.8%; 63.3%)
	III	236	89.7% (85.6%; 94.0%)	76.3% (70.6%; 82.4%)	71.9% (65.8%; 78.6%)	65.6% (59.0%; 73.0%)	59.0% (51.9%; 67.1%)	42.2% (32.3%; 55.2%)
	IV	661	77.8% (74.6%; 81.2%)	58.2% (54.4%; 62.3%)	48.9% (45.0%; 53.2%)	43.9% (39.9%; 48.3%)	39.1% (35.0%; 43.6%)	27.8% (22.7%; 34.1%)
	X/NA	6,461	71.6% (70.5%; 72.8%)	58.9% (57.6%; 60.1%)	51.2% (49.9%; 52.6%)	46.3% (45.0%; 47.8%)	42.4% (40.9%; 43.8%)	29.4% (27.3%; 31.8%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	5,350	77.1% (75.9%; 78.3%)	64.8% (63.4%; 66.2%)	57.8% (56.4%; 59.3%)	53.0% (51.4%; 54.5%)	48.6% (47.0%; 50.3%)	35.3% (32.7%; 38.1%)
	I	500	94.9% (92.6%; 97.1%)	87.6% (84.3%; 91.0%)	81.1% (77.1%; 85.4%)	75.6% (71.0%; 80.5%)	72.6% (67.4%; 78.1%)	59.6% (51.1%; 69.5%)
	II	201	91.8% (87.6%; 96.1%)	77.7% (71.6%; 84.3%)	71.6% (64.8%; 79.2%)	66.7% (59.3%; 75.1%)	61.6% (53.7%; 70.7%)	50.9% (37.8%; 68.6%)
	III	190	92.6% (88.5%; 96.9%)	81.6% (75.8%; 87.9%)	77.1% (70.6%; 84.1%)	72.4% (65.4%; 80.3%)	65.0% (57.2%; 73.8%)	47.1% (35.8%; 62.0%)
	IV	357	79.8% (75.6%; 84.3%)	64.1% (59.0%; 69.6%)	56.5% (51.2%; 62.4%)	51.5% (46.1%; 57.6%)	46.7% (41.0%; 53.2%)	35.4% (28.3%; 44.3%)
	X/NA	4,137	73.3% (71.9%; 74.7%)	60.7% (59.1%; 62.3%)	53.5% (51.9%; 55.2%)	48.7% (47.0%; 50.5%)	44.5% (42.6%; 46.4%)	31.0% (28.0%; 34.3%)
Nasopharynx C11	All	458	85.6% (82.3%; 89.0%)	77.7% (73.8%; 81.9%)	72.2% (67.9%; 76.8%)	69.5% (65.0%; 74.5%)	67.2% (62.3%; 72.4%)	57.2% (50.4%; 65.0%)
	I	5	N<50	N<50	N<50	N<50	N<50	N<50
	II	3	N<50	N<50	N<50	N<50	N<50	N<50
	III	2	N<50	N<50	N<50	N<50	N<50	N<50
	IV	7	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	441	85.9% (82.6%; 89.3%)	77.9% (73.9%; 82.1%)	72.4% (68.0%; 77.1%)	69.9% (65.3%; 74.9%)	67.7% (62.8%; 73.0%)	57.1% (50.1%; 65.1%)

Net Survival Probability, 2013-2022								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Hypopharynx C12-C13	All	2,395	67.1% (65.1%; 69.0%)	51.6% (49.5%; 53.7%)	42.0% (40.0%; 44.2%)	36.4% (34.3%; 38.7%)	32.5% (30.4%; 34.8%)	20.1% (17.4%; 23.2%)
	I	52	98.0% (92.8%; 103.5%)	81.6% (70.7%; 94.2%)	70.7% (57.8%; 86.5%)	63.0% (49.2%; 80.7%)	53.4% (39.0%; 73.3%)	52.1% (35.8%; 75.8%)
	II	37	N<50	N<50	N<50	N<50	N<50	N<50
	III	44	N<50	N<50	N<50	N<50	N<50	N<50
	IV	298	76.0% (71.1%; 81.2%)	51.2% (45.6%; 57.5%)	39.8% (34.2%; 46.2%)	34.7% (29.2%; 41.2%)	29.8% (24.3%; 36.6%)	16.7% (10.3%; 27.0%)
	X/NA	1,964	64.3% (62.1%; 66.5%)	50.3% (48.0%; 52.7%)	41.1% (38.8%; 43.5%)	35.7% (33.3%; 38.2%)	32.1% (29.7%; 34.6%)	19.6% (16.7%; 23.0%)
Larynx (C32)	All	4,813	85.4% (84.3%; 86.5%)	78.4% (77.1%; 79.8%)	73.0% (71.5%; 74.6%)	68.7% (66.9%; 70.4%)	65.8% (63.9%; 67.8%)	46.6% (42.1%; 51.6%)
	I	750	98.9% (97.4%; 100.4%)	98.0% (95.8%; 100.3%)	95.6% (92.6%; 98.8%)	94.2% (90.4%; 98.1%)	93.0% (88.5%; 97.7%)	70.6% (59.6%; 83.6%)
	II	93	91.8% (85.5%; 98.5%)	83.8% (75.3%; 93.3%)	72.2% (61.9%; 84.0%)	68.5% (57.3%; 82.0%)	70.3% (58.4%; 84.8%)	61.4% (39.7%; 95.1%)
	III	192	87.8% (82.9%; 93.0%)	81.9% (76.0%; 88.3%)	75.0% (68.2%; 82.5%)	69.3% (61.7%; 77.8%)	66.5% (58.3%; 75.8%)	37.2% (25.6%; 54.1%)
	IV	540	84.1% (80.9%; 87.5%)	68.7% (64.6%; 73.1%)	59.4% (54.9%; 64.3%)	52.6% (47.8%; 57.8%)	48.2% (43.1%; 53.8%)	33.1% (26.3%; 41.5%)
	X/NA	3,238	82.2% (80.8%; 83.7%)	75.1% (73.5%; 76.9%)	70.0% (68.1%; 71.9%)	65.4% (63.3%; 67.7%)	62.4% (60.0%; 64.8%)	43.7% (38.0%; 50.3%)
Nasal cavity and paranasal sinuses (C30- C31)	All	959	81.9% (79.3%; 84.7%)	69.5% (66.3%; 72.9%)	63.7% (60.2%; 67.6%)	60.0% (56.1%; 64.1%)	59.2% (55.0%; 63.6%)	49.8% (40.7%; 60.9%)
	I	85	94.6% (88.8%; 100.8%)	96.6% (90.2%; 103.4%)	94.2% (85.3%; 104.0%)	92.3% (82.0%; 103.9%)	94.2% (83.0%; 107.0%)	89.4% (64.5%; 123.8%)
	II	79	101.1% (97.5%; 104.8%)	92.8% (84.8%; 101.6%)	89.5% (79.5%; 100.7%)	88.8% (76.5%; 103.0%)	92.1% (78.6%; 107.9%)	47.7% (21.5%; 105.9%)
	III	73	89.0% (81.2%; 97.5%)	78.4% (68.1%; 90.3%)	77.8% (66.0%; 91.6%)	78.1% (65.8%; 92.7%)	81.0% (68.2%; 96.1%)	80.3% (62.0%; 104.2%)
	IV	145	76.4% (69.3%; 84.2%)	60.6% (52.4%; 70.1%)	55.3% (46.6%; 65.5%)	45.9% (36.7%; 57.4%)	41.2% (31.8%; 53.3%)	15.5% (4.8%; 50.4%)
	X/NA	580	78.1% (74.5%; 81.8%)	63.7% (59.4%; 68.3%)	56.5% (52.0%; 61.5%)	53.0% (48.2%; 58.3%)	51.8% (46.7%; 57.5%)	49.3% (40.1%; 60.7%)
Salivary glands (C07-C08)	All	813	85.7% (83.0%; 88.5%)	75.0% (71.6%; 78.6%)	67.7% (63.7%; 71.9%)	65.6% (61.3%; 70.2%)	61.0% (55.7%; 66.8%)	51.2% (42.1%; 62.3%)
	I	115	101.4% (99.6%; 103.1%)	100.8% (97.0%; 104.8%)	99.5% (93.9%; 105.5%)	103.5% (97.7%; 109.6%)	95.7% (83.8%; 109.3%)	85.0% (64.9%; 111.5%)
	II	113	100.5% (97.4%; 103.6%)	93.4% (86.8%; 100.5%)	90.8% (82.7%; 99.7%)	90.7% (81.5%; 101.0%)	87.3% (76.1%; 100.1%)	68.4% (45.9%; 102.1%)

Net Survival Probability, 2013-2022								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	80	98.5% (93.1%; 104.2%)	85.4% (75.6%; 96.4%)	76.4% (64.2%; 90.9%)	78.8% (65.8%; 94.3%)	76.9% (61.9%; 95.4%)	46.4% (25.5%; 84.3%)
	IV	163	86.4% (80.6%; 92.6%)	69.4% (61.6%; 78.2%)	58.3% (49.5%; 68.7%)	47.0% (38.0%; 58.3%)	44.5% (34.6%; 57.3%)	46.6% (33.1%; 65.7%)
	X/NA	342	72.2% (67.2%; 77.7%)	60.5% (54.9%; 66.7%)	51.9% (45.9%; 58.8%)	50.3% (43.9%; 57.6%)	45.3% (37.5%; 54.6%)	36.9% (24.1%; 56.4%)
Other and ill-defined sites (C14)	All	147	53.6% (46.0%; 62.5%)	42.8% (35.3%; 52.0%)	36.5% (29.1%; 45.7%)	30.3% (23.2%; 39.5%)	28.9% (21.8%; 38.4%)	8.4% (3.0%; 23.4%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	146	53.3% (45.7%; 62.2%)	42.4% (34.9%; 51.6%)	35.9% (28.6%; 45.2%)	29.7% (22.7%; 38.9%)	28.3% (21.2%; 37.7%)	8.7% (3.1%; 24.1%)
Females								
Head & Neck (C00-C14, C30- C32)	All	6,961	80.6% (79.6%; 81.6%)	71.9% (70.7%; 73.1%)	67.2% (65.9%; 68.4%)	63.4% (62.0%; 64.8%)	60.8% (59.4%; 62.3%)	48.6% (43.7%; 54.0%)
	I	1,344	96.9% (95.7%; 98.1%)	94.8% (93.1%; 96.4%)	91.6% (89.5%; 93.7%)	89.2% (86.7%; 91.8%)	87.4% (84.5%; 90.4%)	84.4% (77.6%; 91.8%)
	II	582	97.4% (95.5%; 99.2%)	92.2% (89.4%; 95.2%)	87.4% (83.7%; 91.3%)	84.1% (79.7%; 88.9%)	81.8% (76.8%; 87.2%)	68.7% (58.0%; 81.4%)
	III	471	93.0% (90.3%; 95.8%)	82.5% (78.6%; 86.6%)	77.4% (72.9%; 82.1%)	74.3% (69.4%; 79.5%)	71.4% (65.9%; 77.2%)	65.9% (52.7%; 82.4%)
	IV	906	80.0% (77.3%; 82.8%)	66.2% (63.0%; 69.6%)	59.5% (56.1%; 63.2%)	56.3% (52.6%; 60.2%)	52.6% (48.8%; 56.8%)	30.7% (14.8%; 63.6%)
	X/NA	3,834	70.9% (69.4%; 72.4%)	60.6% (58.9%; 62.3%)	55.8% (54.1%; 57.6%)	51.1% (49.3%; 53.0%)	48.3% (46.4%; 50.3%)	35.3% (31.8%; 39.1%)
Lip (C00)	All	166	97.2% (92.8%; 101.8%)	90.0% (83.2%; 97.4%)	86.4% (77.9%; 95.9%)	82.3% (72.2%; 93.9%)	83.6% (72.2%; 96.9%)	86.7% (59.8%; 125.6%)
	I	91	101.1% (96.7%; 105.8%)	96.2% (87.8%; 105.3%)	89.1% (77.5%; 102.5%)	83.6% (69.6%; 100.4%)	86.4% (71.1%; 105.1%)	107.4% (64.0%; 180.1%)
	II	21	N<50	N<50	N<50	N<50	N<50	N<50
	III	11	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	34	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Oral cavity (C02-C05.0, C06)	All	2,409	80.1% (78.4%; 81.9%)	70.2% (68.2%; 72.2%)	65.8% (63.6%; 68.0%)	62.1% (59.8%; 64.5%)	59.8% (57.3%; 62.4%)	46.9% (36.3%; 60.6%)
	I	648	95.9% (94.0%; 97.8%)	93.1% (90.6%; 95.6%)	90.9% (87.9%; 94.0%)	88.7% (85.2%; 92.4%)	85.4% (81.2%; 89.7%)	80.6% (71.8%; 90.5%)
	II	324	96.9% (94.3%; 99.6%)	90.1% (85.9%; 94.5%)	86.2% (80.9%; 91.8%)	81.3% (74.8%; 88.5%)	78.0% (70.7%; 86.0%)	68.7% (53.9%; 87.5%)
	III	261	90.3% (86.2%; 94.6%)	77.4% (71.9%; 83.3%)	73.7% (67.7%; 80.2%)	69.0% (62.4%; 76.3%)	68.5% (61.5%; 76.4%)	64.4% (49.3%; 84.1%)
	IV	557	81.0% (77.7%; 84.5%)	64.8% (60.7%; 69.2%)	57.0% (52.6%; 61.7%)	54.9% (50.3%; 60.0%)	51.3% (46.4%; 56.8%)	25.6% (8.9%; 73.7%)
	X/NA	660	52.0% (48.2%; 56.2%)	40.0% (36.2%; 44.2%)	35.7% (31.9%; 40.1%)	29.8% (26.0%; 34.3%)	29.1% (25.1%; 33.7%)	17.9% (11.4%; 28.2%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	2,667	77.0% (75.3%; 78.6%)	66.9% (65.0%; 68.8%)	61.2% (59.2%; 63.3%)	56.6% (54.5%; 58.8%)	53.2% (51.0%; 55.5%)	38.1% (34.4%; 42.1%)
	I	274	95.7% (93.0%; 98.5%)	93.6% (90.2%; 97.1%)	86.3% (81.5%; 91.4%)	82.8% (77.3%; 88.7%)	79.9% (73.7%; 86.5%)	55.5% (43.2%; 71.3%)
	II	109	95.0% (90.4%; 99.8%)	90.1% (83.8%; 96.8%)	82.9% (74.9%; 91.7%)	79.6% (70.8%; 89.5%)	78.9% (69.6%; 89.5%)	53.2% (36.2%; 78.4%)
	III	85	96.8% (92.3%; 101.5%)	85.1% (77.1%; 94.0%)	77.8% (68.3%; 88.5%)	76.5% (66.4%; 88.2%)	74.5% (63.5%; 87.4%)	71.6% (51.1%; 100.3%)
	IV	154	78.2% (71.8%; 85.2%)	65.0% (57.6%; 73.3%)	58.6% (50.9%; 67.5%)	52.3% (44.4%; 61.7%)	46.9% (38.8%; 56.7%)	35.9% (26.7%; 48.3%)
	X/NA	2,070	72.7% (70.8%; 74.7%)	61.6% (59.5%; 63.8%)	56.4% (54.1%; 58.7%)	51.5% (49.1%; 54.0%)	47.7% (45.3%; 50.4%)	33.3% (29.3%; 37.8%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	2,043	78.9% (77.1%; 80.8%)	68.5% (66.4%; 70.6%)	63.5% (61.2%; 65.8%)	59.2% (56.8%; 61.7%)	56.0% (53.5%; 58.6%)	40.7% (36.4%; 45.5%)
	I	249	95.5% (92.6%; 98.5%)	93.1% (89.5%; 96.9%)	86.6% (81.6%; 91.8%)	83.2% (77.6%; 89.3%)	79.9% (73.5%; 86.9%)	55.5% (42.9%; 71.8%)
	II	100	95.5% (90.9%; 100.3%)	91.0% (84.7%; 97.9%)	84.3% (76.0%; 93.4%)	80.6% (71.5%; 91.0%)	79.8% (70.1%; 90.9%)	58.4% (41.1%; 82.9%)
	III	76	96.2% (91.3%; 101.4%)	84.4% (75.9%; 93.8%)	80.1% (70.5%; 91.1%)	82.3% (72.4%; 93.5%)	80.0% (69.0%; 92.7%)	76.6% (54.8%; 107.0%)
	IV	111	83.1% (76.2%; 90.6%)	66.5% (57.9%; 76.3%)	61.6% (52.7%; 72.1%)	56.2% (46.9%; 67.3%)	52.1% (42.6%; 63.7%)	40.7% (29.8%; 55.6%)
	X/NA	1,524	74.0% (71.7%; 76.3%)	62.4% (59.9%; 65.0%)	57.7% (55.0%; 60.4%)	52.8% (50.1%; 55.8%)	49.4% (46.5%; 52.4%)	34.4% (29.5%; 40.1%)
Nasopharynx C11	All	182	86.2% (81.2%; 91.6%)	82.2% (76.5%; 88.3%)	77.3% (70.9%; 84.3%)	72.3% (65.1%; 80.4%)	70.8% (63.3%; 79.2%)	61.0% (49.1%; 75.8%)

Net Survival Probability, 2013-2022								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	4	N<50	N<50	N<50	N<50	N<50	N<50
	II	4	N<50	N<50	N<50	N<50	N<50	N<50
	III	2	N<50	N<50	N<50	N<50	N<50	N<50
	IV	5	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	167	85.5% (80.2%; 91.3%)	81.0% (75.0%; 87.6%)	78.7% (72.3%; 85.8%)	75.1% (67.8%; 83.2%)	74.5% (66.9%; 82.8%)	63.9% (51.5%; 79.3%)
Hypopharynx C12-C13	All	470	65.2% (60.9%; 69.7%)	54.3% (49.8%; 59.2%)	44.9% (40.3%; 50.0%)	37.8% (33.2%; 43.1%)	31.9% (27.2%; 37.3%)	17.4% (12.0%; 25.0%)
	I	23	N<50	N<50	N<50	N<50	N<50	N<50
	II	5	N<50	N<50	N<50	N<50	N<50	N<50
	III	7	N<50	N<50	N<50	N<50	N<50	N<50
	IV	38	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	397	62.7% (58.0%; 67.7%)	50.8% (46.0%; 56.2%)	41.7% (36.8%; 47.3%)	34.8% (29.9%; 40.5%)	28.8% (24.0%; 34.6%)	16.5% (11.3%; 24.0%)
Larynx (C32)	All	874	85.1% (82.6%; 87.7%)	77.7% (74.7%; 80.8%)	71.8% (68.5%; 75.3%)	68.0% (64.4%; 71.9%)	65.4% (61.5%; 69.5%)	56.6% (50.5%; 63.5%)
	I	140	96.7% (92.9%; 100.5%)	97.0% (92.7%; 101.5%)	95.7% (90.3%; 101.5%)	93.8% (86.9%; 101.3%)	93.9% (86.3%; 102.1%)	100.5% (87.4%; 115.7%)
	II	19	N<50	N<50	N<50	N<50	N<50	N<50
	III	28	N<50	N<50	N<50	N<50	N<50	N<50
	IV	68	77.4% (67.7%; 88.5%)	63.9% (52.9%; 77.1%)	55.0% (43.4%; 69.8%)	53.3% (41.1%; 69.1%)	49.3% (36.7%; 66.1%)	22.3% (9.4%; 53.2%)
	X/NA	619	82.3% (79.2%; 85.6%)	73.6% (70.0%; 77.5%)	67.2% (63.2%; 71.5%)	63.2% (58.8%; 67.8%)	60.6% (56.0%; 65.6%)	49.3% (42.4%; 57.4%)
Nasal cavity and paranasal sinuses (C30- C31)	All	367	78.8% (74.5%; 83.4%)	70.2% (65.1%; 75.6%)	65.7% (60.3%; 71.6%)	62.4% (56.7%; 68.7%)	59.7% (53.6%; 66.6%)	52.3% (41.1%; 66.6%)
	I	42	N<50	N<50	N<50	N<50	N<50	N<50
	II	18	N<50	N<50	N<50	N<50	N<50	N<50
	III	23	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
location	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IV	38	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	246	73.5% (67.8%; 79.6%)	63.7% (57.4%; 70.8%)	59.8% (53.1%; 67.3%)	57.2% (50.3%; 65.1%)	53.5% (46.3%; 61.9%)	38.2% (26.9%; 54.3%)
Salivary glands (C07-C08)	All	598	89.5% (86.7%; 92.4%)	87.8% (84.5%; 91.1%)	87.1% (83.4%; 90.9%)	85.9% (81.6%; 90.5%)	84.8% (79.9%; 90.0%)	73.0% (60.8%; 87.7%)
	I	159	100.0% (98.3%; 101.8%)	99.5% (96.6%; 102.4%)	98.9% (94.9%; 103.0%)	99.1% (94.3%; 104.2%)	102.2% (97.2%; 107.5%)	108.3% (94.1%; 124.6%)
	II	94	99.6% (96.3%; 103.0%)	100.6% (96.6%; 104.7%)	97.5% (91.1%; 104.2%)	97.1% (89.7%; 105.1%)	97.9% (89.2%; 107.4%)	92.8% (68.5%; 125.7%)
	III	64	95.3% (88.6%; 102.4%)	94.8% (86.6%; 103.9%)	94.7% (84.8%; 105.7%)	98.8% (88.4%; 110.3%)	85.4% (69.4%; 105.1%)	48.1% (20.0%; 115.3%)
	IV	83	81.3% (72.9%; 90.6%)	80.5% (71.5%; 90.7%)	77.8% (67.8%; 89.3%)	74.5% (63.5%; 87.5%)	73.2% (61.4%; 87.3%)	52.9% (36.2%; 77.2%)
	X/NA	198	77.9% (71.7%; 84.7%)	73.2% (66.1%; 81.0%)	74.1% (66.5%; 82.6%)	71.2% (62.4%; 81.3%)	69.6% (60.1%; 80.6%)	58.3% (41.2%; 82.4%)
Other and ill-defined sites (C14)	All	47	N<50	N<50	N<50	N<50	N<50	N<50
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	47	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.4. Head & Neck cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	25,832	79.9% (79.4%; 80.4%)	69.9% (69.3%; 70.5%)	63.7% (63.0%; 64.4%)	59.3% (58.6%; 60.1%)	56.1% (55.4%; 56.9%)	42.2% (40.2%; 44.2%)
Males								
Head & Neck (C00-C14, C30-C32)	All	18,871	79.7% (79.1%; 80.3%)	69.1% (68.4%; 69.9%)	62.4% (61.6%; 63.2%)	57.8% (57.0%; 58.7%)	54.4% (53.5%; 55.4%)	39.8% (37.9%; 41.8%)
	I	4,111	96.5% (95.7%; 97.2%)	92.5% (91.4%; 93.6%)	88.7% (87.3%; 90.1%)	85.9% (84.2%; 87.7%)	83.3% (81.3%; 85.4%)	64.4% (58.2%; 71.3%)
	II	2,628	90.0% (88.7%; 91.3%)	82.2% (80.5%; 83.9%)	75.0% (73.0%; 77.0%)	69.7% (67.4%; 72.0%)	66.1% (63.6%; 68.7%)	48.2% (43.3%; 53.5%)
	III	2,963	82.7% (81.2%; 84.2%)	73.1% (71.4%; 74.9%)	66.5% (64.5%; 68.5%)	61.7% (59.6%; 63.9%)	58.0% (55.7%; 60.5%)	38.8% (34.6%; 43.5%)
	IV	29	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	7,069	71.7% (70.6%; 72.8%)	56.6% (55.4%; 57.8%)	47.9% (46.6%; 49.2%)	42.7% (41.4%; 44.0%)	38.5% (37.2%; 39.9%)	26.8% (24.8%; 28.8%)
	IVC	882	42.5% (39.3%; 46.0%)	23.8% (21.0%; 26.9%)	16.7% (14.2%; 19.6%)	12.9% (10.6%; 15.7%)	10.8% (8.5%; 13.6%)	7.0% (4.1%; 11.7%)
	X/NA	1,800	70.1% (67.9%; 72.4%)	58.3% (55.9%; 60.9%)	52.3% (49.7%; 54.9%)	47.0% (44.4%; 49.8%)	45.0% (42.2%; 47.9%)	34.5% (30.3%; 39.2%)
Lip (C00)	All	328	95.3% (92.1%; 98.6%)	90.0% (85.4%; 94.9%)	86.2% (80.5%; 92.2%)	84.3% (77.7%; 91.5%)	84.1% (76.7%; 92.2%)	75.9% (52.4%; 109.8%)
	I	201	99.8% (96.6%; 103.1%)	98.2% (93.1%; 103.5%)	96.5% (89.9%; 103.5%)	94.9% (86.8%; 103.9%)	93.1% (83.5%; 103.8%)	84.2% (53.5%; 132.7%)
	II	50	95.2% (87.3%; 103.7%)	89.2% (78.3%; 101.6%)	81.7% (68.4%; 97.6%)	85.2% (71.4%; 101.8%)	87.1% (72.2%; 105.1%)	97.2% (72.8%; 129.7%)
	III	18	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	18	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	3	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	38	N<50	N<50	N<50	N<50	N<50	N<50
Oral cavity (C02-C05.0, C06)	All	4,305	80.4% (79.2%; 81.7%)	69.4% (67.9%; 70.9%)	62.0% (60.4%; 63.7%)	57.0% (55.3%; 58.8%)	53.4% (51.5%; 55.3%)	38.0% (34.7%; 41.7%)
	I	1,022	96.9% (95.6%; 98.3%)	91.7% (89.6%; 93.8%)	87.4% (84.8%; 90.0%)	83.2% (80.2%; 86.4%)	79.6% (76.0%; 83.4%)	58.0% (49.7%; 67.8%)
	II	647	89.1% (86.5%; 91.8%)	82.6% (79.3%; 86.0%)	74.1% (70.2%; 78.2%)	67.6% (63.1%; 72.4%)	62.7% (57.8%; 68.0%)	44.0% (36.0%; 53.9%)

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	665	82.8% (79.8%; 86.0%)	72.1% (68.4%; 75.9%)	63.7% (59.7%; 68.0%)	58.8% (54.3%; 63.5%)	55.7% (50.9%; 60.9%)	39.9% (31.7%; 50.4%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,698	71.7% (69.5%; 74.0%)	55.4% (53.0%; 58.0%)	46.7% (44.1%; 49.3%)	41.1% (38.6%; 43.9%)	37.3% (34.7%; 40.2%)	24.5% (20.4%; 29.4%)
	IVC	113	37.6% (29.5%; 47.8%)	21.6% (14.9%; 31.3%)	14.1% (8.1%; 24.5%)	12.9% (7.2%; 23.2%)	10.6% (5.2%; 21.3%)	FU<10 y
	X/NA	213	60.4% (54.0%; 67.7%)	48.9% (42.2%; 56.6%)	44.0% (37.2%; 52.0%)	38.5% (31.6%; 46.8%)	37.9% (30.8%; 46.6%)	30.9% (21.6%; 44.2%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	8,060	74.7% (73.8%; 75.7%)	61.9% (60.7%; 63.0%)	54.3% (53.1%; 55.5%)	49.3% (48.0%; 50.5%)	45.2% (43.9%; 46.5%)	32.2% (30.3%; 34.3%)
	I	1,000	92.7% (90.9%; 94.5%)	84.3% (81.7%; 86.9%)	77.6% (74.5%; 80.7%)	72.0% (68.5%; 75.7%)	67.7% (63.8%; 71.8%)	53.1% (46.5%; 60.6%)
	II	977	88.4% (86.2%; 90.7%)	78.1% (75.3%; 81.1%)	70.0% (66.7%; 73.5%)	64.4% (60.7%; 68.2%)	59.8% (55.9%; 64.0%)	41.3% (34.8%; 49.0%)
	III	1,325	81.9% (79.7%; 84.1%)	71.8% (69.2%; 74.5%)	66.5% (63.7%; 69.4%)	61.4% (58.3%; 64.6%)	57.9% (54.7%; 61.3%)	39.8% (33.9%; 46.7%)
	IV	29	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	3,780	70.6% (69.1%; 72.1%)	55.8% (54.2%; 57.5%)	46.9% (45.3%; 48.7%)	42.4% (40.7%; 44.2%)	38.0% (36.2%; 39.9%)	27.1% (24.8%; 29.7%)
	IVC	539	41.0% (37.0%; 45.5%)	21.9% (18.6%; 25.8%)	15.1% (12.2%; 18.6%)	11.4% (8.8%; 14.7%)	8.5% (6.1%; 11.8%)	6.1% (3.8%; 9.9%)
	X/NA	573	62.1% (58.2%; 66.4%)	48.1% (44.0%; 52.5%)	42.2% (38.1%; 46.8%)	36.0% (32.0%; 40.6%)	33.5% (29.4%; 38.1%)	23.0% (18.0%; 29.4%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	5,350	77.1% (75.9%; 78.3%)	64.8% (63.4%; 66.2%)	57.8% (56.4%; 59.3%)	53.0% (51.4%; 54.5%)	48.6% (47.0%; 50.3%)	35.3% (32.7%; 38.1%)
	I	854	93.0% (91.1%; 95.0%)	85.0% (82.3%; 87.8%)	79.2% (75.9%; 82.6%)	73.6% (69.8%; 77.5%)	70.2% (65.9%; 74.7%)	54.7% (47.0%; 63.5%)
	II	703	90.8% (88.5%; 93.3%)	80.6% (77.3%; 84.0%)	72.5% (68.7%; 76.6%)	66.3% (62.0%; 70.9%)	61.4% (56.7%; 66.4%)	44.3% (36.0%; 54.6%)
	III	842	81.9% (79.1%; 84.7%)	71.9% (68.7%; 75.3%)	67.0% (63.5%; 70.7%)	62.8% (59.1%; 66.8%)	57.9% (53.8%; 62.2%)	38.7% (30.1%; 49.8%)
	IV	29	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	2,283	72.0% (70.1%; 73.9%)	57.8% (55.7%; 60.0%)	49.8% (47.7%; 52.1%)	45.7% (43.5%; 48.1%)	41.0% (38.7%; 43.5%)	30.2% (27.1%; 33.6%)
	IVC	282	43.1% (37.6%; 49.4%)	23.4% (18.8%; 29.1%)	18.0% (13.9%; 23.4%)	13.3% (9.7%; 18.4%)	10.9% (7.3%; 16.3%)	8.3% (4.7%; 14.5%)
	X/NA	408	63.2% (58.5%; 68.2%)	49.2% (44.3%; 54.5%)	42.8% (38.0%; 48.2%)	36.5% (31.7%; 42.0%)	34.9% (30.0%; 40.5%)	23.7% (17.9%; 31.4%)

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Nasopharynx C11	All	458	85.6% (82.3%; 89.0%)	77.7% (73.8%; 81.9%)	72.2% (67.9%; 76.8%)	69.5% (65.0%; 74.5%)	67.2% (62.3%; 72.4%)	57.2% (50.4%; 65.0%)
	I	32	N<50	N<50	N<50	N<50	N<50	N<50
	II	88	93.2% (87.6%; 99.2%)	91.0% (84.3%; 98.1%)	87.8% (79.8%; 96.6%)	85.0% (75.8%; 95.4%)	86.4% (77.0%; 96.9%)	68.1% (52.4%; 88.6%)
	III	143	91.0% (86.2%; 96.1%)	88.2% (82.7%; 94.2%)	82.6% (76.0%; 89.8%)	79.1% (71.9%; 87.0%)	80.0% (72.7%; 88.0%)	74.4% (64.7%; 85.6%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	144	78.5% (71.9%; 85.7%)	69.6% (62.2%; 77.8%)	63.0% (55.2%; 71.9%)	60.7% (52.6%; 70.1%)	55.4% (46.7%; 65.7%)	43.4% (30.6%; 61.6%)
	IVC	14	N<50	N<50	N<50	N<50	N<50	N<50
X/NA	37	N<50	N<50	N<50	N<50	N<50	N<50	
Hypopharynx C12-C13	All	2,395	67.1% (65.1%; 69.0%)	51.6% (49.5%; 53.7%)	42.0% (40.0%; 44.2%)	36.4% (34.3%; 38.7%)	32.5% (30.4%; 34.8%)	20.1% (17.4%; 23.2%)
	I	119	90.9% (85.3%; 96.8%)	80.5% (72.9%; 88.8%)	66.2% (57.3%; 76.5%)	59.0% (49.6%; 70.0%)	51.2% (41.5%; 63.1%)	40.8% (29.7%; 56.0%)
	II	192	76.2% (70.1%; 82.9%)	61.6% (54.6%; 69.6%)	50.8% (43.4%; 59.4%)	46.0% (38.5%; 55.1%)	39.4% (31.8%; 49.0%)	20.0% (11.9%; 33.8%)
	III	340	78.2% (73.7%; 83.0%)	64.6% (59.3%; 70.3%)	58.4% (52.8%; 64.6%)	50.2% (44.0%; 57.3%)	48.6% (42.2%; 55.9%)	27.6% (20.2%; 37.6%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,370	67.3% (64.8%; 69.9%)	50.8% (48.1%; 53.7%)	40.2% (37.5%; 43.1%)	34.9% (32.1%; 37.8%)	31.0% (28.2%; 33.9%)	19.8% (16.4%; 23.8%)
	IVC	245	37.3% (31.7%; 44.0%)	18.8% (14.5%; 24.5%)	11.1% (7.7%; 16.1%)	8.3% (5.3%; 13.1%)	5.3% (2.9%; 9.7%)	4.2% (1.9%; 9.6%)
X/NA	132	56.3% (48.3%; 65.6%)	45.6% (37.7%; 55.3%)	40.7% (32.7%; 50.5%)	34.2% (26.4%; 44.2%)	30.2% (22.6%; 40.5%)	21.1% (12.3%; 36.0%)	
Larynx (C32)	All	4,813	85.4% (84.3%; 86.5%)	78.4% (77.1%; 79.8%)	73.0% (71.5%; 74.6%)	68.7% (66.9%; 70.4%)	65.8% (63.9%; 67.8%)	46.6% (42.1%; 51.6%)
	I	1,728	97.7% (96.5%; 98.8%)	96.3% (94.7%; 97.9%)	93.8% (91.7%; 95.9%)	92.0% (89.2%; 94.8%)	90.5% (87.3%; 93.8%)	68.3% (58.1%; 80.4%)
	II	741	90.0% (87.5%; 92.5%)	83.0% (79.9%; 86.3%)	77.0% (73.3%; 80.8%)	71.0% (66.9%; 75.5%)	68.1% (63.5%; 73.0%)	50.5% (42.3%; 60.4%)
	III	738	81.7% (78.7%; 84.8%)	73.5% (70.0%; 77.2%)	66.3% (62.4%; 70.4%)	60.7% (56.5%; 65.2%)	56.1% (51.6%; 61.0%)	31.6% (24.4%; 41.1%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,104	73.7% (71.1%; 76.5%)	60.3% (57.3%; 63.5%)	52.3% (49.1%; 55.7%)	46.1% (42.8%; 49.7%)	41.9% (38.5%; 45.6%)	26.4% (22.0%; 31.7%)
	IVC	121	47.1% (38.8%; 57.1%)	23.2% (16.5%; 32.7%)	16.6% (10.6%; 25.9%)	11.8% (6.4%; 21.8%)	12.1% (6.5%; 22.4%)	FU<10 y

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	380	74.1% (69.5%; 78.9%)	67.7% (62.6%; 73.1%)	61.7% (56.2%; 67.8%)	56.6% (50.8%; 63.2%)	53.8% (47.6%; 60.9%)	38.4% (29.5%; 50.1%)
Nasal cavity and paranasal sinuses (C30-C31)	All	959	81.9% (79.3%; 84.7%)	69.5% (66.3%; 72.9%)	63.7% (60.2%; 67.6%)	60.0% (56.1%; 64.1%)	59.2% (55.0%; 63.6%)	49.8% (40.7%; 60.9%)
	I	111	95.8% (91.0%; 100.9%)	92.7% (86.0%; 100.0%)	88.9% (80.4%; 98.4%)	87.7% (78.3%; 98.3%)	89.5% (79.4%; 100.9%)	87.2% (65.8%; 115.5%)
	II	110	99.6% (95.6%; 103.8%)	93.4% (86.4%; 101.0%)	89.7% (80.4%; 99.9%)	88.0% (77.0%; 100.6%)	91.1% (78.9%; 105.3%)	70.1% (39.5%; 124.3%)
	III	122	88.0% (81.5%; 95.0%)	80.1% (71.9%; 89.3%)	73.5% (63.4%; 85.2%)	72.3% (61.5%; 84.9%)	75.2% (64.1%; 88.4%)	66.6% (48.1%; 92.2%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	292	72.7% (67.4%; 78.4%)	56.2% (50.3%; 62.8%)	49.9% (43.8%; 56.9%)	44.4% (38.0%; 52.0%)	42.3% (35.6%; 50.2%)	29.5% (17.7%; 49.2%)
	IVC	41	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	286	81.7% (76.9%; 86.8%)	66.4% (60.5%; 72.8%)	60.7% (54.4%; 67.8%)	55.9% (49.2%; 63.5%)	52.4% (45.2%; 60.8%)	51.6% (41.3%; 64.3%)
Salivary glands (C07-C08)	All	813	85.7% (83.0%; 88.5%)	75.0% (71.6%; 78.6%)	67.7% (63.7%; 71.9%)	65.6% (61.3%; 70.2%)	61.0% (55.7%; 66.8%)	51.2% (42.1%; 62.3%)
	I	120	101.7% (100.0%; 103.3%)	101.5% (97.8%; 105.3%)	100.5% (95.1%; 106.3%)	104.8% (99.2%; 110.8%)	97.9% (86.3%; 111.1%)	81.1% (55.2%; 119.2%)
	II	123	97.5% (93.3%; 102.0%)	92.4% (85.7%; 99.6%)	87.6% (79.2%; 96.9%)	87.8% (78.5%; 98.2%)	82.7% (71.5%; 95.7%)	65.3% (43.8%; 97.3%)
	III	105	91.8% (85.1%; 99.0%)	83.2% (74.0%; 93.5%)	74.1% (62.4%; 88.0%)	77.4% (64.4%; 92.9%)	65.4% (46.0%; 92.8%)	39.8% (20.4%; 77.8%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	212	78.4% (72.5%; 84.9%)	59.6% (52.5%; 67.7%)	49.7% (42.0%; 58.8%)	40.4% (32.8%; 49.8%)	35.6% (27.5%; 46.0%)	37.4% (26.8%; 52.1%)
	IVC	67	49.9% (38.9%; 64.0%)	38.0% (27.4%; 52.6%)	30.7% (20.5%; 46.0%)	23.6% (13.8%; 40.3%)	22.6% (12.9%; 39.8%)	FU<10 y
	X/NA	186	85.5% (79.9%; 91.4%)	72.7% (65.7%; 80.5%)	63.6% (55.8%; 72.4%)	62.4% (54.3%; 71.7%)	62.0% (53.4%; 71.9%)	55.4% (40.2%; 76.3%)
Other and ill-defined sites (C14)	All	147	53.6% (46.0%; 62.5%)	42.8% (35.3%; 52.0%)	36.5% (29.1%; 45.7%)	30.3% (23.2%; 39.5%)	28.9% (21.8%; 38.4%)	8.4% (3.0%; 23.4%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IVA-B	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	146	53.3% (45.7%; 62.2%)	42.4% (34.9%; 51.6%)	35.9% (28.6%; 45.2%)	29.7% (22.7%; 38.9%)	28.3% (21.2%; 37.7%)	8.7% (3.1%; 24.1%)
Females								
Head & Neck (C00-C14, C30-C32)	All	6,961	80.6% (79.6%; 81.6%)	71.9% (70.7%; 73.1%)	67.2% (65.9%; 68.4%)	63.4% (62.0%; 64.8%)	60.8% (59.4%; 62.3%)	48.6% (43.7%; 54.0%)
	I	1,740	96.0% (94.9%; 97.2%)	93.7% (92.2%; 95.3%)	90.3% (88.3%; 92.3%)	87.7% (85.5%; 90.1%)	86.2% (83.6%; 88.9%)	83.8% (77.9%; 90.1%)
	II	1,081	92.7% (90.9%; 94.6%)	85.5% (83.1%; 88.0%)	81.4% (78.5%; 84.4%)	76.9% (73.5%; 80.4%)	75.2% (71.5%; 79.1%)	59.2% (51.9%; 67.6%)
	III	1,044	83.3% (80.9%; 85.8%)	73.2% (70.3%; 76.2%)	67.3% (64.1%; 70.6%)	63.5% (60.0%; 67.1%)	59.6% (55.9%; 63.6%)	51.1% (43.3%; 60.4%)
	IV	10	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	2,374	68.8% (66.9%; 70.8%)	55.7% (53.7%; 57.9%)	49.5% (47.4%; 51.8%)	45.5% (43.3%; 47.8%)	42.1% (39.8%; 44.6%)	24.4% (16.1%; 37.0%)
	IVC	221	36.5% (30.6%; 43.6%)	23.6% (18.5%; 30.2%)	16.0% (11.6%; 22.1%)	14.8% (10.4%; 21.0%)	13.7% (9.4%; 19.9%)	8.4% (4.8%; 14.8%)
	X/NA	700	72.9% (69.5%; 76.5%)	63.7% (59.9%; 67.7%)	61.0% (57.1%; 65.2%)	54.5% (50.3%; 59.1%)	51.7% (47.3%; 56.5%)	40.4% (33.8%; 48.3%)
Lip (C00)	All	166	97.2% (92.8%; 101.8%)	90.0% (83.2%; 97.4%)	86.4% (77.9%; 95.9%)	82.3% (72.2%; 93.9%)	83.6% (72.2%; 96.9%)	86.7% (59.8%; 125.6%)
	I	102	100.3% (95.8%; 105.0%)	96.1% (88.3%; 104.6%)	89.2% (78.5%; 101.4%)	83.3% (70.4%; 98.4%)	86.1% (72.1%; 102.8%)	100.8% (63.9%; 159.1%)
	II	24	N<50	N<50	N<50	N<50	N<50	N<50
	III	11	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	13	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	16	N<50	N<50	N<50	N<50	N<50	N<50
Oral cavity (C02-C05.0, C06)	All	2,409	80.1% (78.4%; 81.9%)	70.2% (68.2%; 72.2%)	65.8% (63.6%; 68.0%)	62.1% (59.8%; 64.5%)	59.8% (57.3%; 62.4%)	46.9% (36.3%; 60.6%)
	I	690	95.9% (94.0%; 97.7%)	92.8% (90.3%; 95.3%)	90.2% (87.1%; 93.4%)	87.2% (83.6%; 90.9%)	83.6% (79.5%; 88.0%)	79.3% (70.9%; 88.6%)
	II	387	92.7% (89.6%; 96.0%)	85.9% (81.6%; 90.3%)	80.7% (75.5%; 86.2%)	75.7% (69.5%; 82.5%)	73.3% (66.6%; 80.8%)	64.9% (52.1%; 81.0%)

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	325	82.8% (78.4%; 87.5%)	69.3% (63.9%; 75.1%)	65.4% (59.7%; 71.7%)	59.9% (53.7%; 66.9%)	59.5% (53.0%; 66.9%)	55.4% (42.5%; 72.3%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	879	65.7% (62.5%; 69.1%)	51.2% (47.8%; 54.8%)	45.0% (41.5%; 48.8%)	42.3% (38.7%; 46.3%)	40.0% (36.2%; 44.2%)	17.3% (6.2%; 47.9%)
	IVC	43	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	125	61.0% (52.6%; 70.6%)	51.1% (42.5%; 61.5%)	48.5% (39.7%; 59.4%)	42.1% (33.3%; 53.2%)	39.9% (31.0%; 51.4%)	26.4% (16.4%; 42.6%)
Pharynx (C01, C05.1-C05.9, C09-C13)	All	2,667	77.0% (75.3%; 78.6%)	66.9% (65.0%; 68.8%)	61.2% (59.2%; 63.3%)	56.6% (54.5%; 58.8%)	53.2% (51.0%; 55.5%)	38.1% (34.4%; 42.1%)
	I	443	93.1% (90.6%; 95.8%)	90.1% (86.9%; 93.3%)	84.1% (80.0%; 88.3%)	80.8% (76.2%; 85.7%)	78.0% (72.9%; 83.6%)	57.6% (47.3%; 70.1%)
	II	405	90.2% (87.1%; 93.4%)	81.0% (76.9%; 85.3%)	77.7% (73.2%; 82.5%)	72.7% (67.6%; 78.2%)	70.8% (65.3%; 76.6%)	49.5% (39.7%; 61.6%)
	III	452	80.7% (77.0%; 84.7%)	71.6% (67.3%; 76.1%)	65.2% (60.6%; 70.2%)	61.4% (56.4%; 66.8%)	58.1% (52.9%; 63.9%)	47.2% (38.1%; 58.6%)
	IV	10	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,079	70.4% (67.7%; 73.3%)	57.3% (54.3%; 60.4%)	50.2% (47.1%; 53.4%)	45.4% (42.3%; 48.8%)	41.0% (37.8%; 44.5%)	28.5% (23.7%; 34.2%)
	IVC	108	30.9% (23.3%; 41.0%)	20.9% (14.4%; 30.2%)	12.8% (7.8%; 21.1%)	11.9% (7.0%; 20.1%)	9.9% (5.5%; 17.8%)	8.1% (4.0%; 16.2%)
	X/NA	212	69.0% (62.8%; 75.8%)	57.1% (50.5%; 64.5%)	56.0% (49.3%; 63.7%)	46.6% (39.5%; 54.9%)	44.1% (37.0%; 52.5%)	28.1% (20.6%; 38.3%)
Oropharynx C01;C05.1-C05.9;C09-C10	All	2,043	78.9% (77.1%; 80.8%)	68.5% (66.4%; 70.6%)	63.5% (61.2%; 65.8%)	59.2% (56.8%; 61.7%)	56.0% (53.5%; 58.6%)	40.7% (36.4%; 45.5%)
	I	388	93.8% (91.2%; 96.5%)	90.4% (87.1%; 93.9%)	85.2% (80.9%; 89.6%)	82.1% (77.2%; 87.2%)	79.3% (73.8%; 85.2%)	58.2% (47.3%; 71.7%)
	II	308	90.4% (86.8%; 94.0%)	80.9% (76.2%; 85.9%)	77.5% (72.3%; 83.1%)	71.8% (65.9%; 78.2%)	69.6% (63.4%; 76.5%)	47.9% (37.7%; 60.9%)
	III	329	81.6% (77.3%; 86.1%)	72.5% (67.5%; 77.9%)	68.5% (63.1%; 74.3%)	65.8% (60.1%; 72.1%)	62.1% (56.0%; 68.9%)	51.0% (39.6%; 65.6%)
	IV	10	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	782	72.6% (69.5%; 75.9%)	59.1% (55.6%; 62.7%)	52.1% (48.5%; 55.9%)	47.4% (43.7%; 51.4%)	43.7% (39.9%; 47.8%)	31.9% (26.0%; 39.2%)
	IVC	73	33.3% (24.1%; 46.0%)	18.3% (11.3%; 29.6%)	12.1% (6.5%; 22.6%)	12.3% (6.6%; 22.9%)	9.4% (4.5%; 19.3%)	6.9% (2.9%; 16.7%)
	X/NA	172	69.7% (62.9%; 77.2%)	56.5% (49.3%; 64.9%)	56.2% (48.8%; 64.8%)	49.9% (42.1%; 59.1%)	48.2% (40.3%; 57.7%)	30.1% (21.5%; 42.1%)

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Nasopharynx C11	All	182	86.2% (81.2%; 91.6%)	82.2% (76.5%; 88.3%)	77.3% (70.9%; 84.3%)	72.3% (65.1%; 80.4%)	70.8% (63.3%; 79.2%)	61.0% (49.1%; 75.8%)
	I	13	N<50	N<50	N<50	N<50	N<50	N<50
	II	47	N<50	N<50	N<50	N<50	N<50	N<50
	III	48	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	55	75.0% (64.1%; 87.7%)	71.8% (60.5%; 85.2%)	70.1% (58.5%; 84.1%)	70.7% (59.0%; 84.8%)	67.6% (55.0%; 83.0%)	55.6% (39.0%; 79.1%)
	IVC	7	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	12	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	All	470	65.2% (60.9%; 69.7%)	54.3% (49.8%; 59.2%)	44.9% (40.3%; 50.0%)	37.8% (33.2%; 43.1%)	31.9% (27.2%; 37.3%)	17.4% (12.0%; 25.0%)
	I	44	N<50	N<50	N<50	N<50	N<50	N<50
	II	51	79.4% (68.6%; 92.0%)	65.5% (53.1%; 80.9%)	63.9% (51.2%; 79.8%)	61.2% (47.9%; 78.2%)	57.6% (43.5%; 76.3%)	28.5% (10.2%; 79.7%)
	III	76	73.0% (63.5%; 84.0%)	63.0% (52.7%; 75.4%)	45.3% (34.7%; 59.2%)	33.0% (22.6%; 48.2%)	31.7% (21.3%; 47.3%)	19.4% (9.5%; 39.9%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	243	61.9% (56.0%; 68.5%)	48.0% (41.9%; 55.0%)	39.3% (33.3%; 46.5%)	33.4% (27.5%; 40.7%)	25.7% (20.1%; 33.0%)	11.2% (6.4%; 19.8%)
	IVC	28	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	28	N<50	N<50	N<50	N<50	N<50	N<50
Larynx (C32)	All	874	85.1% (82.6%; 87.7%)	77.7% (74.7%; 80.8%)	71.8% (68.5%; 75.3%)	68.0% (64.4%; 71.9%)	65.4% (61.5%; 69.5%)	56.6% (50.5%; 63.5%)
	I	295	96.6% (93.9%; 99.3%)	95.8% (92.5%; 99.3%)	93.3% (89.1%; 97.8%)	92.2% (87.2%; 97.5%)	93.6% (88.2%; 99.4%)	98.6% (87.2%; 111.5%)
	II	139	91.1% (86.1%; 96.3%)	81.8% (75.1%; 89.0%)	77.6% (70.1%; 85.8%)	70.6% (62.1%; 80.1%)	67.6% (58.7%; 77.8%)	47.3% (34.7%; 64.3%)
	III	145	84.7% (78.6%; 91.3%)	74.6% (67.3%; 82.7%)	64.6% (56.4%; 74.0%)	60.2% (51.4%; 70.5%)	50.8% (41.3%; 62.5%)	38.0% (24.0%; 60.2%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	197	71.4% (65.2%; 78.2%)	57.6% (50.8%; 65.2%)	49.1% (42.1%; 57.1%)	43.9% (36.9%; 52.4%)	42.3% (35.1%; 50.9%)	22.7% (14.6%; 35.2%)
	IVC	24	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	74	78.5% (69.3%; 88.9%)	71.7% (61.5%; 83.6%)	64.8% (53.8%; 77.9%)	60.0% (47.9%; 75.1%)	52.7% (40.4%; 68.6%)	46.4% (32.0%; 67.2%)
Nasal cavity and paranasal sinuses (C30-C31)	All	367	78.8% (74.5%; 83.4%)	70.2% (65.1%; 75.6%)	65.7% (60.3%; 71.6%)	62.4% (56.7%; 68.7%)	59.7% (53.6%; 66.6%)	52.3% (41.1%; 66.6%)
	I	57	96.1% (90.4%; 102.1%)	97.6% (91.9%; 103.7%)	94.3% (85.8%; 103.7%)	93.5% (84.0%; 104.0%)	94.5% (84.9%; 105.2%)	84.1% (62.1%; 114.0%)
	II	24	N<50	N<50	N<50	N<50	N<50	N<50
	III	34	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	103	60.6% (51.5%; 71.4%)	49.6% (40.1%; 61.4%)	47.9% (38.2%; 60.0%)	40.5% (30.6%; 53.6%)	39.5% (29.4%; 53.1%)	17.6% (7.2%; 43.0%)
	IVC	16	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	133	83.9% (77.4%; 91.0%)	72.5% (64.5%; 81.4%)	70.0% (61.6%; 79.7%)	66.7% (57.8%; 77.1%)	60.9% (51.3%; 72.3%)	48.1% (34.2%; 67.7%)
Salivary glands (C07-C08)	All	598	89.5% (86.7%; 92.4%)	87.8% (84.5%; 91.1%)	87.1% (83.4%; 90.9%)	85.9% (81.6%; 90.5%)	84.8% (79.9%; 90.0%)	73.0% (60.8%; 87.7%)
	I	167	100.1% (98.4%; 101.8%)	99.6% (96.9%; 102.4%)	99.2% (95.4%; 103.1%)	99.6% (95.0%; 104.4%)	101.0% (95.6%; 106.8%)	107.3% (94.3%; 122.2%)
	II	109	99.2% (95.9%; 102.6%)	100.6% (96.7%; 104.6%)	98.8% (93.0%; 104.9%)	99.8% (93.1%; 107.0%)	102.6% (94.7%; 111.2%)	86.8% (61.9%; 121.8%)
	III	81	92.2% (85.4%; 99.6%)	91.3% (83.0%; 100.5%)	91.5% (81.7%; 102.5%)	92.7% (81.4%; 105.4%)	79.9% (65.5%; 97.5%)	55.3% (26.8%; 114.2%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	114	77.9% (69.9%; 86.9%)	73.8% (64.6%; 84.2%)	74.5% (64.6%; 85.8%)	70.3% (59.3%; 83.3%)	67.6% (55.7%; 82.1%)	43.2% (25.0%; 74.8%)
	IVC	30	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	98	88.1% (81.1%; 95.8%)	85.4% (77.2%; 94.5%)	84.0% (74.9%; 94.2%)	79.6% (68.0%; 93.1%)	79.4% (67.2%; 93.8%)	80.5% (58.0%; 111.7%)
Other and ill-defined sites (C14)	All	47	N<50	N<50	N<50	N<50	N<50	N<50
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2013-2022								
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IVA-B	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	47	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

5. CANCER SURVIVAL TRENDS



5.1. Head & Neck cancer survival trends: by tumour stage

5.1.1. Head & Neck cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	All	9586	79.2% (78.3%; 80.1%)	59.9% (58.8%; 61.0%)	51.2% (50.0%; 52.3%)	3149	81.3% (79.9%; 82.8%)	65.6% (63.8%; 67.4%)	57.6% (55.6%; 59.6%)
	I	1736	96.3% (95.1%; 97.5%)	88.5% (86.5%; 90.7%)	82.3% (79.7%; 85.0%)	647	96.5% (94.8%; 98.3%)	88.3% (85.2%; 91.5%)	83.0% (79.3%; 86.9%)
	II	1117	88.0% (85.9%; 90.1%)	71.8% (68.9%; 74.9%)	63.3% (59.9%; 66.8%)	393	89.7% (86.4%; 93.0%)	80.6% (76.2%; 85.3%)	71.9% (66.6%; 77.6%)
	III	1325	81.8% (79.6%; 84.1%)	60.3% (57.5%; 63.2%)	51.1% (48.1%; 54.2%)	403	87.0% (83.5%; 90.6%)	70.0% (65.2%; 75.1%)	57.5% (52.1%; 63.4%)
	IV	0	N<50	N<50	N<50	0	N<50	N<50	N<50
	IVA-B	3315	71.9% (70.3%; 73.5%)	46.1% (44.3%; 47.9%)	35.8% (34.0%; 37.6%)	945	73.4% (70.6%; 76.4%)	49.9% (46.6%; 53.3%)	41.9% (38.6%; 45.4%)
	IVC	375	47.1% (42.2%; 52.5%)	18.6% (14.8%; 23.2%)	9.8% (7.0%; 13.6%)	98	42.9% (34.0%; 54.0%)	23.3% (15.4%; 35.2%)	17.5% (10.8%; 28.3%)
	X/NA	1797	75.1% (73.0%; 77.2%)	57.8% (55.3%; 60.4%)	49.6% (46.8%; 52.5%)	685	75.7% (72.3%; 79.2%)	60.7% (56.7%; 65.0%)	53.1% (48.7%; 57.8%)
2013-2017	All	9700	78.9% (78.1%; 79.8%)	60.7% (59.6%; 61.8%)	52.5% (51.4%; 53.7%)	3390	79.8% (78.4%; 81.3%)	64.9% (63.2%; 66.7%)	58.3% (56.4%; 60.3%)
	I	1948	96.0% (94.9%; 97.2%)	87.2% (85.3%; 89.2%)	81.7% (79.2%; 84.3%)	763	95.4% (93.6%; 97.2%)	88.6% (85.7%; 91.6%)	83.3% (79.7%; 87.1%)
	II	1232	89.5% (87.6%; 91.5%)	74.7% (71.9%; 77.5%)	65.9% (62.7%; 69.2%)	492	90.1% (87.2%; 93.1%)	77.7% (73.4%; 82.2%)	72.0% (67.1%; 77.3%)
	III	1409	81.6% (79.5%; 83.8%)	65.1% (62.4%; 68.0%)	56.1% (53.1%; 59.2%)	445	83.3% (79.6%; 87.1%)	66.2% (61.5%; 71.2%)	57.6% (52.5%; 63.2%)
	IV	0	N<50	N<50	N<50	0	N<50	N<50	N<50
	IVA-B	3746	72.0% (70.5%; 73.5%)	47.2% (45.5%; 48.9%)	37.5% (35.8%; 39.3%)	1206	69.9% (67.3%; 72.7%)	49.3% (46.4%; 52.4%)	42.1% (39.1%; 45.3%)
	IVC	418	41.0% (36.4%; 46.1%)	15.1% (11.9%; 19.2%)	9.8% (7.0%; 13.7%)	106	40.1% (31.7%; 50.7%)	20.5% (14.0%; 29.9%)	18.3% (12.1%; 27.6%)

Period	Stage	Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		
	X/NA	1129 71.0% (68.3%; 73.9%)	52.7% (49.6%; 56.1%)	45.3% (42.0%; 48.9%)	434 73.0% (68.7%; 77.6%)	60.7% (55.8%; 66.1%)	51.0% (45.7%; 57.0%)		
2018-2022	All	9439 80.4% (79.5%; 81.2%)	63.9% (62.8%; 65.1%)	56.3% (54.7%; 57.9%)	3666 81.2% (79.9%; 82.6%)	69.1% (67.4%; 70.9%)	63.3% (61.1%; 65.7%)		
	I	2194 96.8% (95.8%; 97.9%)	90.0% (88.0%; 92.0%)	84.3% (80.6%; 88.1%)	984 96.5% (95.0%; 98.0%)	91.4% (88.7%; 94.1%)	89.7% (86.1%; 93.5%)		
	II	1409 90.4% (88.7%; 92.2%)	75.2% (72.3%; 78.1%)	66.0% (62.0%; 70.3%)	592 94.8% (92.7%; 97.0%)	84.4% (80.5%; 88.4%)	77.5% (71.7%; 83.8%)		
	III	1558 83.5% (81.6%; 85.6%)	67.7% (64.9%; 70.6%)	60.9% (56.9%; 65.2%)	600 83.4% (80.3%; 86.7%)	68.2% (64.0%; 72.8%)	62.6% (57.2%; 68.5%)		
	IV	29 N<50	N<50	N<50	10 N<50	N<50	N<50		
	IVA-B	3341 71.3% (69.7%; 72.9%)	48.7% (46.8%; 50.6%)	40.0% (37.7%; 42.4%)	1175 67.4% (64.7%; 70.3%)	49.9% (46.9%; 53.2%)	41.9% (38.2%; 46.0%)		
	IVC	465 43.8% (39.4%; 48.6%)	18.3% (14.7%; 22.7%)	11.4% (8.1%; 16.1%)	115 33.2% (25.5%; 43.2%)	11.0% (5.9%; 20.5%)	FU<5y		
	X/NA	677 68.6% (65.0%; 72.3%)	51.1% (47.0%; 55.7%)	43.4% (38.6%; 48.7%)	270 72.8% (67.5%; 78.5%)	61.8% (55.6%; 68.5%)	53.1% (45.8%; 61.6%)		

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6. CANCER MORTALITY



6.1. Head & Neck cancer mortality: by region

6.1.1. Head & Neck cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	0	0	0	1	0	1	0	0	4	11	26	51	78	98	84	61	41	30	17	3	506	9.6
	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.3]	[0.0]	[0.0]	[1.1]	[2.9]	[6.5]	[12.6]	[21.5]	[32.0]	[31.7]	[35.0]	[31.4]	[38.6]	[60.6]	[55.0]	[8.9]	(8.7; 10.4)
Brussels	0	0	0	0	0	0	0	0	0	1	2	4	6	2	6	3	7	3	3	0	37	10.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[5.0]	[11.7]	[22.0]	[9.6]	[35.9]	[26.1]	[82.8]	[59.4]	[137.9]	[0.0]	[6.2]	(6.7; 13.3)
Flanders	0	0	0	1	0	0	0	0	2	6	14	30	49	64	53	39	31	19	11	1	320	9.7
	[0.0]	[0.0]	[0.0]	[0.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.8]	[6.0]	[12.3]	[22.2]	[34.1]	[32.7]	[34.2]	[35.9]	[36.8]	[60.0]	[27.9]	[9.7]	(8.6; 10.8)
Wallonia	0	0	0	0	0	1	0	0	2	4	10	17	23	32	25	19	3	8	3	2	149	9.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[1.7]	[3.2]	[8.1]	[13.6]	[20.0]	[32.7]	[28.9]	[39.2]	[8.3]	[38.2]	[39.6]	[142.2]	[8.3]	(7.7; 10.8)
Females																						
Belgium	0	0	0	0	0	0	0	0	0	3	7	14	18	29	33	24	22	15	5	3	173	2.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.8]	[3.5]	[4.8]	[8.9]	[11.1]	[11.3]	[11.9]	[11.1]	[7.5]	[15.6]	[3.0]	(2.3; 3.2)
Brussels	0	0	0	0	0	0	0	0	0	0	2	1	2	2	2	3	2	2	1	0	17	3.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[5.4]	[3.0]	[6.7]	[8.2]	[9.3]	[18.5]	[14.6]	[19.7]	[17.4]	[0.0]	[2.7]	(1.8; 5.1)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	0	0	0	0	0	0	2	3	10	11	22	21	14	15	6	3	3	110	2.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[1.3]	[4.2]	[5.0]	[11.4]	[12.1]	[10.5]	[12.9]	[7.1]	[7.5]	[26.7]	[3.3]	(2.4; 3.5)
Wallonia	0	0	0	0	0	0	0	0	0	1	2	3	5	5	10	7	5	7	1	0	46	2.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.6]	[2.4]	[4.1]	[4.6]	[9.9]	[11.0]	[9.1]	[17.5]	[4.9]	[0.0]	[2.5]	(1.6; 3.0)

7. CANCER MORTALITY TRENDS



7.1. Head & Neck cancer mortality trends: by region

7.1.1. Head & Neck cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	N	601	636	620	569	594	616	585	572	624	642	626	600	603	565	539	544	552	506			
	CR	11.8	12.4	12.1	11.0	11.4	11.7	11.0	10.7	11.5	11.8	11.4	10.9	10.9	10.1	9.6	9.7	9.8	8.9			
	ESR2013	14.5	14.9	14.3	13.0	13.2	13.5	13.0	12.3	13.3	13.8	12.8	12.2	12.3	11.1	10.5	10.6	10.5	9.6	-2.4 (-2.9; -1.9)	2004-2021	
																				-1.6 (-2.2; -1.0)	2004-2017	
																					-4.8 (-7.0; -2.6)	2018-2021
Brussels	N	60	52	61	61	56	58	49	53	65	54	55	53	53	53	49	53	38	37			
	CR	12.5	10.8	12.5	12.3	11.1	11.2	9.3	9.8	11.8	9.6	9.7	9.3	9.1	9.1	8.4	8.9	6.4	6.2			
	ESR2013	17.7	15.9	17.9	17.6	16.0	16.0	13.9	15.5	17.5	15.7	15.1	14.9	15.6	13.7	13.4	13.8	10.0	10.0	-2.8 (-3.6; -2.0)	2004-2021	
																				-0.8 (-2.1; 0.5)	2004-2015	
																					-6.4 (-8.8; -3.9)	2016-2021
Flanders	N	365	353	350	328	319	343	350	341	348	372	384	391	376	348	327	328	343	320			
	CR	12.3	11.8	11.7	10.9	10.5	11.2	11.3	11.0	11.1	11.8	12.1	12.3	11.7	10.8	10.1	10.1	10.5	9.7			
	ESR2013	14.9	13.6	13.5	12.5	11.7	12.6	12.7	11.9	12.3	13.0	12.8	12.8	12.3	11.2	10.2	10.4	10.5	9.7	-1.7 (-2.3; -1.1)	2004-2021	
Wallonia	N	176	231	209	180	219	215	186	178	211	216	187	156	174	164	163	163	171	149			
	CR	10.7	14.0	12.6	10.8	13.1	12.7	10.9	10.4	12.2	12.5	10.7	8.9	9.9	9.3	9.2	9.2	9.6	8.3			

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
ESR2013	12.9	16.7	15.0	13.0	15.4	14.7	13.2	12.4	14.2	14.7	12.3	10.0	11.3	10.5	10.4	10.4	10.7	9.2	-2.7 (-3.6; -1.7)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Head & Neck cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period			
Belgium	N	176	155	150	154	164	163	169	171	183	191	177	203	191	222	172	194	151	173					
	CR	3.3	2.9	2.8	2.9	3.0	3.0	3.1	3.1	3.3	3.4	3.1	3.6	3.3	3.9	3.0	3.3	2.6	3.0					
	ESR2013	3.4	3.0	2.9	2.9	3.0	2.9	3.1	3.1	3.3	3.4	3.1	3.4	3.2	3.7	2.7	3.1	2.4	2.8	-1.0 (-1.8; -0.1)	2004-2021			
																				0.8 (-0.3; 1.8)	2004-2017			
																					-6.3 (-10.0; -2.5)	2018-2021		
Brussels	N	29	23	21	20	15	18	17	18	20	14	15	19	28	27	12	16	13	17					
	CR	5.6	4.4	4.0	3.7	2.8	3.3	3.0	3.1	3.4	2.4	2.5	3.2	4.6	4.4	2.0	2.6	2.1	2.7					
	ESR2013	6.2	4.5	4.8	4.3	2.9	3.9	3.1	3.6	4.4	2.9	3.1	4.0	5.9	5.8	2.4	3.3	2.6	3.4					
																					-2.0 (-4.5; 0.5)	2004-2021		
Flanders	N	78	81	68	85	87	86	89	87	98	112	94	114	115	121	103	108	104	110					
	CR	2.6	2.6	2.2	2.7	2.8	2.7	2.8	2.7	3.0	3.5	2.9	3.5	3.5	3.7	3.1	3.2	3.1	3.3					
	ESR2013	2.6	2.6	2.2	2.7	2.7	2.6	2.8	2.7	3.0	3.3	2.8	3.2	3.2	3.3	2.7	2.9	2.7	2.9					
																					0.7 (-0.1; 1.4)	2004-2021		
																						2.2 (1.1; 3.2)	2004-2016	
																						-2.8 (-5.6; 0.0)	2017-2021	
Wallonia	N	69	51	61	49	62	59	63	66	65	65	68	70	48	74	57	70	34	46					
	CR	4.0	2.9	3.5	2.8	3.5	3.3	3.5	3.6	3.6	3.6	3.7	3.8	2.6	4.0	3.1	3.8	1.8	2.5					
	ESR2013	4.1	3.1	3.6	2.9	3.6	3.3	3.4	3.7	3.5	3.7	3.6	3.7	2.5	3.9	2.9	3.5	1.7	2.3					
																						-2.5 (-4.2; -0.9)	2004-2021	
																							0.4 (-2.3; 3.2)	2004-2015
																							-7.7 (-12.7; -2.5)	2016-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024